{"gene":"GATA4","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":2015,"finding":"GATA4 is normally degraded by p62-mediated selective autophagy; during senescence, this autophagic degradation is suppressed, stabilizing GATA4. Stabilized GATA4 then activates NF-κB to initiate the senescence-associated secretory phenotype (SASP). GATA4 activation in this context depends on the DNA damage response kinases ATM and ATR, but not on p53 or p16(INK4a).","method":"Genetic loss-of-function, protein stability assays, autophagy flux assays, epistasis experiments with ATM/ATR inhibitors and p62 knockdown, NF-κB reporter assays","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (genetic KD, pharmacologic inhibition, epistasis, reporter assays) in a high-profile study; mechanistic pathway clearly delineated","pmids":["26404840"],"is_preprint":false},{"year":2004,"finding":"GATA4 is sumoylated by SUMO-1 at lysine 366, which enhances its transcriptional activity. PIAS1 acts as the E3 SUMO ligase for GATA4 through its RING finger domain. Mutation of K366R reduces GATA4 nuclear occupancy, suggesting SUMO modification also modulates nuclear localization.","method":"In vitro sumoylation assay, site-directed mutagenesis (K366R), co-transfection reporter assays, subcellular localization analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro sumoylation assay plus mutagenesis plus functional reporter assays in a single study; modification site and E3 ligase both identified","pmids":["15337742"],"is_preprint":false},{"year":2010,"finding":"Hdac2 physically interacts with GATA4 and mediates its deacetylation; this interaction is stabilized by the homeodomain factor Hopx. Hopx/Hdac2-mediated deacetylation of GATA4 impairs its ability to transactivate cell cycle genes, restraining cardiomyocyte proliferation during embryonic development. Loss of Hopx and Hdac2 leads to GATA4 hyperacetylation, increased cardiomyocyte proliferation, and upregulation of GATA4 target genes.","method":"Co-immunoprecipitation, genetic knockout (Hopx and Hdac2 null mice), cardiomyocyte proliferation assays, transactivation assays, interaction domain mapping","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — Co-IP plus in vivo genetic models plus functional transactivation assays; multiple orthogonal approaches in a single study","pmids":["20833366"],"is_preprint":false},{"year":2016,"finding":"The GATA4-G296S disease-causing missense mutation disrupts physical interaction with TBX5, particularly at cardiac super-enhancers, leading to failure of TBX5 recruitment and dysregulation of cardiac septation genes. The mutation also causes failure of GATA4/TBX5-mediated repression at non-cardiac genes and aberrant chromatin opening at endothelial/endocardial promoters.","method":"iPS-derived cardiomyocytes from patients, ChIP-seq, ATAC-seq, co-occupancy analysis, functional contractility and calcium handling assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — human disease iPSC model with genome-wide chromatin occupancy and functional assays; multiple orthogonal methods in a high-impact study","pmids":["27984724"],"is_preprint":false},{"year":2002,"finding":"GATA4, Nkx2-5, and SRF form higher-order complexes on the cardiac alpha-actin (alphaCA) promoter and synergistically activate its transcription. SRF DNA binding is required to recruit Nkx2-5 and GATA4 to the promoter, and their recruitment enhances SRF DNA-binding affinity. A DNA-binding-defective Nkx2-5 mutant retains coactivation activity in the presence of SRF and GATA4.","method":"Cotransfection reporter assays in CV1 fibroblasts and Schneider 2 cells, embryonic stem cell endogenous gene induction, DNA-binding mutant analysis, promoter deletion/mutation analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple reporter and mutant analyses in heterologous systems; physical interaction inferred from functional cooperativity and mutant data but direct Co-IP not reported in abstract","pmids":["11983708"],"is_preprint":false},{"year":2005,"finding":"PKC phosphorylation of GATA4 enhances its DNA-binding activity. STAT-1 physically interacts with GATA4 and synergistically activates ANF and other growth factor-inducible promoters. GATA factors can recruit STAT proteins to target promoters via GATA binding sites, enabling STAT proteins to act as growth factor-inducible coactivators of tissue-specific transcription.","method":"Co-immunoprecipitation, luciferase reporter assays, EMSA (DNA-binding activity), PKC inhibitor/activator treatments, STAT binding site mutations","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP and reporter assays; multiple methods in one lab but replication not established","pmids":["16260600"],"is_preprint":false},{"year":2014,"finding":"Cyclin D2 (CycD2) physically interacts with GATA4 through a discrete N-terminal activation domain (aa 129-152) and acts as a CDK-independent coactivator, synergistically enhancing GATA-dependent transcription. GATA4 recruits CycD2 to its target promoters. Human congenital heart disease mutations in this domain disrupt CycD2-GATA4 synergy. CycD1 does not potentiate GATA4 activity.","method":"Co-immunoprecipitation, ChIP, luciferase reporter assays, domain deletion/mutation analysis, Xenopus embryo cardiogenesis assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — Co-IP plus ChIP plus reporter assays plus in vivo Xenopus validation; multiple orthogonal methods in one study","pmids":["24474767"],"is_preprint":false},{"year":2012,"finding":"The N-terminal domain of GATA4 (aa 129–152) is required for cardiogenic activity and for transcriptional synergy with BAF60c. A serine at position 105 (S105, a known MAPK phosphorylation target) is required for GATA4-dependent cardiomyocyte survival and hypertrophy but dispensable for cardiogenesis. S105 is differentially required for transcriptional synergy with SRF but not TBX5 or NKX2.5.","method":"Domain deletion and point mutagenesis, luciferase reporter assays, cardiomyocyte survival assays, Xenopus embryo cardiogenesis assays","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — in vitro mutagenesis combined with in vivo Xenopus assays; dissection of distinct functional domains","pmids":["22473995"],"is_preprint":false},{"year":2014,"finding":"GATA4 and TBX5 co-localize and physically interact in the developing atria and ventricles (demonstrated by co-immunoprecipitation). Gata4 and Tbx5 cooperatively and directly regulate Cdk4 transcription (by ChIP and transactivation assays), while only Tbx5 activates Cdk2. Loss of myocardial GATA4 combined with Tbx5 heterozygosity (but not endocardial GATA4 loss) causes thin myocardium, reduced cardiomyocyte proliferation, and atrioventricular septation defects.","method":"Co-immunoprecipitation, co-localization, ChIP, luciferase transactivation assays, conditional Cre-loxP knockout (myocardial vs endocardial lineages)","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — reciprocal Co-IP, ChIP, transactivation, and lineage-specific in vivo genetics; multiple orthogonal methods","pmids":["24858909"],"is_preprint":false},{"year":2007,"finding":"CHIP (carboxyl terminus of Hsp70-interacting protein), an E3 ubiquitin ligase, promotes GATA4 protein degradation via the ubiquitin-proteasome system. High glucose increases CHIP mRNA expression, leading to increased GATA4 protein degradation; proteasome inhibition reverses this. CHIP knockdown prevents high glucose-induced GATA4 depletion.","method":"Proteasome inhibitor treatment, CHIP overexpression and siRNA knockdown, UPS reporter assay, western blotting, in vivo diabetic mouse models","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function for CHIP plus pharmacologic inhibition plus in vivo validation; single lab","pmids":["17525155"],"is_preprint":false},{"year":2014,"finding":"Caspase-1 cleaves GATA4 both in vivo and in vitro, generating a truncated protein that retains DNA binding ability but lacks transcriptional activation domains and acts as a dominant-negative regulator of GATA4. Caspase-1 is rapidly activated in cardiomyocyte nuclei upon doxorubicin treatment. Inhibition of caspase-1 alone is sufficient to rescue GATA4 degradation and cardiomyocyte death. HSP70 binds directly to GATA4 and masks the caspase recognition motif, protecting it from cleavage.","method":"In vitro caspase-1 cleavage assay, dominant-negative mutant analysis, cardiomyocyte cell death assays, caspase-1 inhibition, Co-immunoprecipitation (HSP70-GATA4)","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro cleavage assay plus dominant-negative functional analysis plus Co-IP; multiple orthogonal methods in a single study","pmids":["25501827"],"is_preprint":false},{"year":2022,"finding":"CHD4 (catalytic subunit of NuRD complex) physically interacts with GATA4, NKX2-5, and TBX5 during embryonic heart development (demonstrated by mass spectrometry and co-IP). GATA4-CHD4 complexes occupy and repress specific cardiac gene targets, including silencers of skeletal muscle (Acta1) and smooth muscle (Myh11) genes in the embryonic heart; deletion of these silencers leads to inappropriate misexpression of these genes in the heart.","method":"Mass spectrometry, co-immunoprecipitation, ChIP-seq, RNA-seq, in vivo CRISPR/Cas9 silencer deletion","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — MS-based protein interaction, Co-IP, genome-wide occupancy, and in vivo genetic validation of specific enhancers/silencers; multiple orthogonal methods","pmids":["35450884"],"is_preprint":false},{"year":2022,"finding":"ERRγ interacts physically with GATA4 to cooperatively activate transcription of cardiomyocyte-specific contractile genes (but not metabolic genes, which require PGC-1α independently of GATA4). ERRγ and GATA4 co-occupy cardiac enhancers/super-enhancers genome-wide. A disease-causing GATA4 mutation diminishes PGC-1α/ERR/GATA4 cooperativity.","method":"Co-immunoprecipitation, ChIP-seq, hiPSC-CM differentiation, luciferase reporter assays, disease mutation functional analysis","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and genome-wide ChIP-seq plus reporter assays; single lab, multiple methods","pmids":["35418170"],"is_preprint":false},{"year":2022,"finding":"GATA4 functions as a pioneer transcription factor whose lineage-specific chromatin occupancy is directed by co-expressed non-pioneer transcription factors: NKX2-5 in cardiomyocytes and ETS1 in endocardial cells. Both NKX2-5 and ETS1 physically interact with GATA4 (by Co-IP) and re-direct its pioneer binding genome-wide, augmenting chromatin opening. ETS1 displays greater potency than NKX2-5 as a pioneer partner. GATA4 and ETS1 cooperatively stimulate endothelial cell enhancer activity.","method":"Lineage-specific Cre-activated GATA4 biotinylation followed by ChIP-seq, ATAC-seq, co-immunoprecipitation, scRNA-seq, luciferase reporter assays, conditional endothelial Gata4 knockout","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — lineage-specific genome-wide occupancy, ATAC-seq, Co-IP, scRNA-seq, and in vivo KO with reporter validation; comprehensive mechanistic dissection","pmids":["36263775"],"is_preprint":false},{"year":2022,"finding":"GATA4 forms a homomultimer; residues 308–326 are necessary for multimerization. Acetylation of GATA4 by p300 induces its multimerization and activates DNA-binding activity. Suppression of GATA4 multimerization represses GATA4/p300-induced gene transcription and inhibits phenylephrine-induced hypertrophic response in cardiomyocytes without reducing acetylation.","method":"Protein multimerization assays, domain mutagenesis, acetylation assays, DNA-binding activity measurement, cardiomyocyte hypertrophy assays","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical multimerization assays plus mutagenesis plus functional hypertrophy assays; single lab","pmids":["35173540"],"is_preprint":false},{"year":2017,"finding":"GATA4 controls liver sinusoidal endothelial cell (LSEC) specification; its deletion causes transformation of discontinuous liver sinusoids into continuous capillaries, characterized by ectopic basement membrane deposition, continuous EC layer formation, and increased VE-cadherin expression. Ectopic GATA4 expression in continuous ECs downregulates continuous EC transcripts and upregulates LSEC-associated genes.","method":"LSEC-specific conditional Gata4 knockout (Cre-loxP), GATA4 overexpression in cultured ECs, histology, electron microscopy, transcriptomic profiling","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — lineage-specific in vivo KO plus gain-of-function in cultured cells plus structural validation; replicated in subsequent paper (PMID 32916216)","pmids":["28218627"],"is_preprint":false},{"year":2020,"finding":"In adult LSECs, GATA4 loss triggers a profibrotic angiocrine switch involving de novo endothelial expression of PDGFB (a hepatic stellate cell-activating cytokine). MYC activation mediates ectopic Pdgfb expression by increasing chromatin accessibility at the Pdgfb locus, downstream of GATA4 loss. GATA4 thus protects against perisinusoidal liver fibrosis by repressing MYC activation and profibrotic angiocrine signaling at the chromatin level.","method":"LSEC-specific adult Gata4 conditional KO, ChIP-seq, ATAC-seq, gene expression profiling, dietary and chemical fibrosis models, human scRNA-seq datasets","journal":"Journal of hepatology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — conditional in vivo KO with chromatin-level mechanistic data (ChIP-seq, ATAC-seq) plus multiple fibrosis models plus human data","pmids":["32916216"],"is_preprint":false},{"year":2021,"finding":"GATA4 directly represses EPAS1 (encoding HIF2α) transcription in hepatic stellate cells. Overexpression of GATA4 in hepatic stellate cells promotes liver fibrosis regression (deactivation); lack of GATA4 in adult mice causes hepatic stellate cell activation and liver fibrosis. Stabilization of HIF2α in hepatic stellate cells leads to liver fibrosis.","method":"Conditional Gata4 knockout in mice, adenoviral Gata4 overexpression, CCl4 fibrosis model, ChIP for GATA4 at EPAS1 promoter, HIF2α stabilization experiments","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo KO and OE plus ChIP validation of direct EPAS1 repression; single lab","pmids":["34699385"],"is_preprint":false},{"year":2017,"finding":"GATA4 directly activates a cis-regulatory element at Gli1 in vitro (luciferase assay) and occupies this element in vivo (ChIP), placing Gata4 directly upstream of Hedgehog signaling components in the second heart field. Gata4 haploinsufficiency in the SHF causes Hedgehog signaling defects; constitutive SHF Hh signaling activation rescues AVSDs in Gata4 SHF-specific heterozygotes. A parallel cell-cycle defect (via PTEN/cell cycle) acts independently of Hh.","method":"SHF-specific conditional Gata4 heterozygote mice, luciferase reporter assay (Gli1 cis-element), ChIP (Gata4 at Gli1 element), Pten knockdown rescue, constitutive Smo activation rescue","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct target identification (luciferase + ChIP) combined with in vivo epistasis rescue experiments","pmids":["28167794"],"is_preprint":false},{"year":2019,"finding":"Gata4 directly represses Gata6 transcription via repressive cis-regulatory sites within 1 kb upstream of the Gata6 TSS, identified by ChIP-qPCR and luciferase reporter assay. In Gata4 haploinsufficient SHF cells, enhanced Gata6 expression is observed, consistent with GATA4-mediated repression of Gata6.","method":"ChIP-qPCR, luciferase reporter assay, Gata4 haploinsufficient mouse model with SHF gene expression analysis","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and reporter assays support direct repression; single lab, consistent with in vivo data","pmids":["31120883"],"is_preprint":false},{"year":2011,"finding":"GATA4 is a pioneer factor for estrogen receptor alpha (ERα) in osteoblasts: maximal GATA4 binding to chromatin precedes ERα binding, GATA4 is required for H3K4 dimethylation at ERα binding sites, and GATA4 knockdown reduces ERα recruitment to DNA. GATA4 and ERα co-occupy chromatin near osteoblast-specific genes controlling differentiation.","method":"ChIP-seq (GATA4 and ERα), ChIP for H3K4me2, GATA4 knockdown with ERα recruitment analysis","journal":"Molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq plus functional KD; single lab, pioneer factor role defined by sequential binding and chromatin mark analysis","pmids":["21566084"],"is_preprint":false},{"year":2017,"finding":"GATA4 directly binds to two Runx2 promoters and an enhancer region (by ChIP). GATA4 binding maintains open chromatin (H3K4me2, H3K27ac marks) at the Runx2 locus; GATA4 knockdown reduces open chromatin marks and increases H3K27me2 (closed chromatin mark) at Runx2, reducing Runx2 expression and osteoblast mineralization in vitro and in vivo.","method":"ChIP (GATA4, H3K4me2, H3K27ac, H3K27me2), DNase I hypersensitivity assay, Gata4 conditional KO (Col1a1-Cre), osteoblast differentiation assays","journal":"JBMR plus","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-based chromatin analysis plus in vivo KO; single lab, pioneer factor role supported by chromatin accessibility data","pmids":["30035248"],"is_preprint":false},{"year":2003,"finding":"GATA-4 binds to the erythropoietin (EPO) gene promoter with the most prominent binding activity among GATA factors expressed in hepatocytes (by EMSA and in vivo ChIP). RNAi-mediated inhibition of GATA-4 expression dramatically reduces Epo gene transcription in Hep3B hepatoma cells.","method":"EMSA, chromatin immunoprecipitation (in vivo), siRNA knockdown with RT-PCR quantification of Epo transcription","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo DNA binding plus siRNA functional validation; single lab","pmids":["14583613"],"is_preprint":false},{"year":2011,"finding":"GATA4 regulates Sertoli cell function including blood-testis barrier (BTB) integrity and lactate metabolism. GATA4 depletion in Sertoli cells alters expression of tight/adherens junction genes (Tjp1, Cldn12, Vcl, Tnc, Csk) and extracellular matrix genes, reduces tight junction protein-1 levels, disrupts junctional complexes, decreases epithelial membrane resistance, and impairs lactate production.","method":"Conditional Sertoli cell Gata4 KO (Amhr2-Cre), siRNA knockdown in TM4 cells, microarray, qRT-PCR, western blotting, immunocytochemistry, metabolomic profiling","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo conditional KO plus in vitro gene silencing plus metabolomics; single lab","pmids":["26974005"],"is_preprint":false},{"year":2020,"finding":"Parkin (E3 ubiquitin ligase) directly interacts with GATA4 (by co-immunoprecipitation) and promotes its ubiquitination. Parkin overexpression decreases GATA4 protein (but not mRNA) in the kidney; Parkin-mediated GATA4 degradation limits downstream GATA4/GAS1 signaling and reduces premature senescence, inflammation, and fibrosis in diabetic nephropathy.","method":"Co-immunoprecipitation, Parkin overexpression and knockout in mice, GATA4 ubiquitination assay, high-glucose cell culture model","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ubiquitination assay plus in vivo KO/OE; single lab","pmids":["32436607"],"is_preprint":false},{"year":2009,"finding":"GATA4 inhibits doxorubicin-induced autophagy in cardiomyocytes as a mechanism of cardioprotection. GATA4 overexpression upregulates Bcl2 expression and suppresses DOX-induced activation of autophagy-related genes. GATA4 depletion triggers autophagy that renders cardiomyocytes more sensitive to DOX toxicity.","method":"LC3-II autophagic flux assays, bafilomycin A1 treatment, GATA4 siRNA and adenoviral overexpression, cell death assays, Bcl2 mRNA/protein analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple autophagy flux assays plus genetic gain/loss-of-function with mechanistic target (Bcl2); single lab","pmids":["19901028"],"is_preprint":false},{"year":2015,"finding":"Notch downstream effectors HEY1, HEY2, and HEYL differentially regulate GATA4-dependent promoters (STAR protein, P450 aromatase, 3β-HSD), and HEY/HES binding sites are present in these promoters. Notch signaling thus represses GATA4-induced steroidogenic gene expression.","method":"Constitutively active Notch constructs, Notch inhibitor treatment of follicles and Leydig cells, luciferase reporter assays with GATA4-dependent promoters, HEY/HES binding site analysis","journal":"Reproduction","confidence":"Low","confidence_rationale":"Tier 3 / Weak — reporter assays in cell lines; direct physical interaction not shown; single lab, limited mechanistic depth","pmids":["26183893"],"is_preprint":false},{"year":2022,"finding":"Nuclear PKM2 (S37P-PKM2) in cardiomyocytes interacts with GATA4, GATA6, and P53. Nuclear PKM2 prevents caspase-1-dependent cleavage and degradation of GATA4/6. TRIM35 (E3 ubiquitin ligase) promotes ubiquitination-dependent loss of nuclear PKM2, which in turn destabilizes GATA4/6 and permits P53 accumulation, leading to cardiac dysfunction.","method":"Co-immunoprecipitation (nuclear PKM2 with GATA4/6), cardiomyocyte-specific PKM2 and TRIM35 transgenic/KO mice, caspase-1 cleavage assays, cardiac function measurements","journal":"Science translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus in vivo genetic models plus caspase cleavage mechanistic link; single lab","pmids":["36322626"],"is_preprint":false},{"year":2018,"finding":"GATA4 directly binds the VEGFA and VEGFC promoters and enhances their transcription in fibroblast-like synoviocytes (FLS). GATA4 loss-of-function attenuates VEGF secretion from RA FLS, reduces endothelial cell proliferation, migration, and tube formation, and suppresses collagen-induced arthritis development and RA-augmented angiogenesis in vivo.","method":"ChIP (GATA4 at VEGFA/VEGFC promoters), GATA4 siRNA knockdown, endothelial tube formation and migration assays, CIA mouse model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-based direct target identification plus in vitro and in vivo loss-of-function; single lab","pmids":["29717129"],"is_preprint":false},{"year":2011,"finding":"GATA4 (together with Sp1) directly regulates transcription of the erythropoietin receptor (EpoR) in cardiomyocytes. GATA4 and Sp1 bind the EpoR 5' flanking region (by EMSA and ChIP). Forced GATA4 expression induces EpoR mRNA; GATA4 knockdown (in vitro and in an inducible shRNA transgenic mouse) reduces EpoR transcription. The Sp1 site is essential for GATA4-mediated EpoR transcription.","method":"EMSA, ChIP, luciferase reporter assays, siRNA knockdown, adenoviral GATA4 overexpression, inducible shRNA transgenic mice","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA plus ChIP plus in vivo transgenic validation; single lab","pmids":["21029371"],"is_preprint":false},{"year":2019,"finding":"Gata4 directly represses EPAS1 (HIF2α) in hepatic stellate cells (by ChIP). GATA4 overexpression in hepatic stellate cells induces fibrosis regression; GATA4 absence causes hepatic stellate cell activation and fibrosis.","method":"ChIP, adenoviral Gata4 overexpression, conditional Gata4 KO in mice, CCl4 fibrosis model","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-based direct target identification with in vivo gain/loss-of-function; single lab","pmids":["34699385"],"is_preprint":false},{"year":2023,"finding":"Intestinal epithelial GATA4 controls bacterial colonization and inflammatory immunity in the proximal small intestine by regulating retinol metabolism and luminal IgA. Loss of jejunal GATA4 permits pathogenic inflammatory responses (including segmented filamentous bacteria-driven IL-17 immunity) that disrupt barrier function and increase mortality upon infection.","method":"Intestinal epithelium-specific Gata4 conditional KO, germ-free mouse colonization experiments, gene expression analysis, IgA measurement, retinol metabolism analysis, in vivo infection model","journal":"Immunity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo conditional KO with mechanistic pathway (retinol metabolism, IgA) identification; single study","pmids":["36630917"],"is_preprint":false},{"year":2011,"finding":"GATA4 regulates Sertoli cell function in adult mice; conditional deletion of Gata4 in Sertoli cells (Amhr2-Cre) causes age-dependent testicular atrophy, impaired spermatogenesis, decreased sperm quantity and motility, increased blood-testis barrier permeability, and loss of fertility.","method":"Conditional Sertoli cell Gata4 knockout (Amhr2-Cre/loxP), histology, RT-PCR, sperm analysis, fertility testing","journal":"Molecular and cellular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo conditional KO with multiple defined cellular phenotypes; single lab","pmids":["21172404"],"is_preprint":false},{"year":2011,"finding":"GATA4 physically interacts with Sp1 (demonstrated by GST pull-down assay) and synergistically activates the ANF promoter. ERK1/2-mediated phosphorylation of GATA4 enhances the affinity between GATA4 and Sp1. Both GATA4 and Sp1 are recruited to the ANF promoter during phenylephrine-induced hypertrophy (by ChIP). Sp3 antagonizes this interaction and represses transcriptional synergy.","method":"GST pull-down, ChIP, luciferase reporter assays, hypertrophic cardiomyocyte model (phenylephrine), ERK inhibitor treatment","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — GST pull-down plus ChIP plus reporter assays; single lab","pmids":["20874724"],"is_preprint":false},{"year":2016,"finding":"GATA4 and GATA6 repress transcription through the sonic hedgehog endoderm-specific enhancer MACS1 in the pancreatic endoderm; GATA-binding sites within MACS1 are necessary for this repressive activity. Loss of both Gata4 and Gata6 in the pancreas leads to ectopic hedgehog pathway activation and conversion of pancreatic fates into intestinal or stomach lineages.","method":"Conditional Gata4/Gata6 double KO (Pdx1-Cre), luciferase reporter assays (MACS1 enhancer with GATA-site mutations), in situ hybridization, immunostaining for lineage markers","journal":"Development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct repressor activity via reporter assays with GATA-site mutations plus in vivo genetic validation; single lab","pmids":["26932670"],"is_preprint":false},{"year":2021,"finding":"Rubicon, a negative regulator of autophagy, prevents autophagic degradation of GATA4 in Sertoli cells. Rubicon-null Sertoli cells show elevated autophagy flux and reduced GATA4 protein levels, causing spermatogenesis defects. Androgens regulate Rubicon levels in testis, thereby indirectly controlling GATA4 protein stability through autophagic degradation.","method":"Rubicon systemic and Sertoli cell-specific KO mice, autophagy flux assays, GATA4 protein quantification, androgen antagonist treatment","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo Sertoli-specific KO plus autophagy flux analysis plus pharmacologic manipulation; single lab","pmids":["34351902"],"is_preprint":false},{"year":2019,"finding":"Kindlin-2 suppresses GATA4 expression by binding to the GATA4 promoter and recruiting histone methyltransferase SUV39H1, which deposits repressive H3K9 di- and tri-methylation marks. Cardiac-specific Kindlin-2 deletion in mice causes hypertrophic cardiomyopathy with markedly elevated GATA4 expression.","method":"ChIP (Kindlin-2, SUV39H1, H3K9me2/3 at GATA4 promoter), co-immunoprecipitation (Kindlin-2/SUV39H1), cardiac-specific Kindlin-2 KO mice, isoproterenol treatment","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus Co-IP plus in vivo KO; single lab","pmids":["31767831"],"is_preprint":false},{"year":2016,"finding":"GATA4 and GATA6 occupy chromatin near the Dll1 (Notch ligand) transcription start site (by ChIP), suggesting direct regulation of Dll1. Double knockout of GATA4 and GATA6 in intestinal epithelium reduces Notch signaling (decreased Dll1 and Olfm4 expression), increases goblet cell differentiation, and increases proliferation.","method":"Double conditional KO (Villin-Cre), ChIP for GATA4 at Dll1 TSS, cell-type marker analysis, Notch pathway gene expression","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus in vivo double KO with Notch pathway phenotype; single lab","pmids":["24929016"],"is_preprint":false},{"year":2016,"finding":"GATA4 binds chromatin near Cyclin D2 (Ccnd2), Cdk6, and Frizzled 5 (Fzd5) genes in developing intestinal epithelium (by ChIP), and their transcripts are reduced in GATA4-deficient intestinal epithelium, placing them as direct GATA4 targets controlling early intestinal epithelial proliferation.","method":"ChIP (GATA4 at Ccnd2, Cdk6, Fzd5), SHH-Cre Gata4 conditional KO embryos, proliferation assays, qRT-PCR","journal":"Cellular and molecular gastroenterology and hepatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-based direct target identification plus in vivo KO phenotype; single lab","pmids":["27066525"],"is_preprint":false},{"year":2012,"finding":"The Gata4 G295S mutation functions as a hypomorph in vivo: it can activate downstream targets in endoderm but not in the developing heart. It causes cardiomyocyte proliferation deficits and decreased cardiac expression of CCND2 (a direct Gata4 target and cyclin family member). In vitro, the mutant protein has reduced DNA-binding affinity and transcriptional activity and abolishes physical interaction with TBX5.","method":"Gata4 G295S knock-in mice, compound mutants with Gata4 null allele, cardiomyocyte proliferation analysis, gene expression (Ccnd2), in vitro transcriptional and DNA-binding assays","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo knock-in mouse model with defined proliferation phenotype plus in vitro mechanistic dissection; single lab","pmids":["22589735"],"is_preprint":false},{"year":2022,"finding":"A GATA4-dependent secretory program (including chemokine CCL2) promotes non-cell-autonomous tumor suppression by recruiting cytotoxic CD8 T cells. GATA4-dependent tumor suppression in mice requires cytotoxic CD8 T cells and is partially dependent on CCL2.","method":"Gata4 loss-of-function and overexpression mouse tumor models, CD8 T cell depletion, CCL2 neutralization, tumor growth assays","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo mouse tumor models with immune cell depletion epistasis; single lab","pmids":["35017504"],"is_preprint":false},{"year":2017,"finding":"GATA4 directly binds the GNAI3 promoter in dental papilla mesenchymal cells (confirmed by dual-luciferase and ChIP assays both in vitro and in vivo). GATA4 deletion reduces GNAI3 expression, and GNAI3 knockdown impairs odonto/osteogenic differentiation of stem cells of dental apical papilla.","method":"Wnt1-Cre Gata4 conditional KO mice, ChIP, dual-luciferase assay, GNAI3 siRNA knockdown, stem cell differentiation assays","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter assay plus in vivo KO; single lab","pmids":["28484278"],"is_preprint":false},{"year":2011,"finding":"GATA-4 binds to a GATA site in the hepcidin (HAMP) promoter (by EMSA and gel retardation), and mutation of this site impairs hepcidin promoter activity. GATA-4 co-transfection enhances hepcidin promoter activity, and siRNA-mediated GATA4 knockdown reduces endogenous hepcidin expression in HepG2 cells. The GATA-binding site is also required for IL-6-induced hepcidin expression but not BMP-6 response.","method":"EMSA, luciferase reporter assays with GATA-site mutations, GATA4 siRNA knockdown, co-transfection in hepatoma cells","journal":"The Biochemical journal","confidence":"Low","confidence_rationale":"Tier 3 / Weak — EMSA plus reporter and siRNA in hepatoma cell line; no ChIP or in vivo validation; single lab","pmids":["21609320"],"is_preprint":false},{"year":2018,"finding":"Meox1 activates Gata4 transcription directly; Meox1 occupies the Gata4 promoter (demonstrated by ChIP) and activates Gata4 promoter activity (luciferase assay). Meox1-driven pathological hypertrophy is mediated through downstream Gata4 activation; Gata4 knockdown abolishes Meox1-induced hypertrophy.","method":"ChIP (Meox1 at Gata4 promoter), luciferase reporter assay, Gata4 siRNA rescue, Meox1 overexpression and knockdown mouse models (TAC, FHCM)","journal":"Cardiovascular research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter plus in vivo mouse models; single lab","pmids":["29155983"],"is_preprint":false},{"year":2023,"finding":"SIRT7 (class III histone deacetylase) promotes deacetylation of GATA4, inhibiting its transcriptional activity. GATA4 normally induces ovarian cancer cell senescence by inhibiting Wnt signaling; SIRT7-mediated deacetylation of GATA4 suppresses this senescence-inducing activity and promotes tumor progression.","method":"Co-immunoprecipitation (SIRT7-GATA4), gain/loss-of-function experiments in OC cell lines, luciferase reporter assays, nude mouse xenograft model","journal":"Gynecologic oncology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — Co-IP plus reporter assays plus xenograft; deacetylation mechanism inferred without direct acetylation site mapping; single lab","pmids":["36804620"],"is_preprint":false}],"current_model":"GATA4 is a zinc-finger pioneer transcription factor whose activity is governed by multiple post-translational modifications (sumoylation by PIAS1 at K366, acetylation by p300 promoting homomultimerization, deacetylation by HDAC2/Hopx or SIRT7, phosphorylation by MAPK/PKC, caspase-1-mediated cleavage, and proteasomal degradation via CHIP or Parkin), and which exerts its transcriptional effects through lineage-specific interactions with co-factors including TBX5, NKX2-5, ETS1, SRF, BAF60c, Cyclin D2, ERRγ/PGC-1α, STAT1, and the CHD4/NuRD repressor complex; in cardiomyocytes and endocardial cells it acts as a pioneer factor whose genome occupancy is directed by partner TFs (NKX2-5 or ETS1), it controls cardiomyocyte proliferation through direct transcription of CCND2 and CDK4, and it regulates senescence/SASP by being a selective autophagy substrate whose stabilization (dependent on ATM/ATR) activates NF-κB."},"narrative":{"mechanistic_narrative":"GATA4 is a zinc-finger pioneer transcription factor that establishes and maintains lineage-specific gene expression programs across cardiac, endothelial, endodermal, skeletal, and gonadal tissues by opening chromatin and directing partner transcription factors to their targets [PMID:36263775, PMID:21566084]. Its pioneering activity is lineage-resolved: co-expressed non-pioneer factors NKX2-5 (cardiomyocytes) and ETS1 (endocardial cells) physically bind GATA4 and redirect its genome-wide occupancy, augmenting chromatin opening, and GATA4 likewise acts upstream of estrogen-receptor-alpha and Runx2 by depositing activating chromatin marks before partner recruitment in osteoblasts [PMID:36263775, PMID:21566084, PMID:30035248]. In the developing heart GATA4 forms higher-order complexes with TBX5, NKX2-5, SRF, Cyclin D2, ERRγ, and BAF60c to activate contractile and cell-cycle genes, and it cooperates with TBX5 to directly transactivate the cyclins CCND2/CDK4 driving cardiomyocyte proliferation; the human disease G296S/G295S mutation disrupts the GATA4–TBX5 interaction at cardiac super-enhancers, causing septation defects and proliferation deficits [PMID:27984724, PMID:11983708, PMID:24474767, PMID:24858909, PMID:35418170, PMID:22589735]. GATA4 also functions as a direct transcriptional repressor through the CHD4/NuRD complex and through repressive cis-elements, silencing skeletal/smooth muscle genes in the heart, repressing GATA6, hedgehog enhancers, and EPAS1/HIF2α in stellate cells [PMID:35450884, PMID:31120883, PMID:26932670, PMID:34699385]. Beyond the heart GATA4 specifies liver sinusoidal endothelial cell identity and protects against perisinusoidal fibrosis by repressing MYC-driven profibrotic angiocrine signaling, and controls intestinal epithelial immunity, Sertoli cell barrier function, and steroidogenesis [PMID:28218627, PMID:32916216, PMID:36630917, PMID:21172404]. GATA4 protein abundance is governed by an extensive set of post-translational controls: sumoylation by PIAS1 at K366 enhances activity and nuclear occupancy, p300 acetylation drives homomultimerization and DNA binding while HDAC2/Hopx and SIRT7 reverse it, MAPK/PKC/ERK phosphorylation enhances DNA binding and cofactor affinity, and the protein is destroyed by CHIP- and Parkin-mediated proteasomal degradation, caspase-1 cleavage, and p62/Rubicon-regulated selective autophagy [PMID:15337742, PMID:20833366, PMID:35173540, PMID:20874724, PMID:17525155, PMID:32436607, PMID:25501827, PMID:34351902]. In senescence, suppression of autophagic GATA4 turnover stabilizes the protein in an ATM/ATR-dependent manner, activating NF-κB to drive the senescence-associated secretory phenotype [PMID:26404840].","teleology":[{"year":2002,"claim":"Established that GATA4 does not act alone but assembles into higher-order transcription factor complexes on cardiac promoters, defining the combinatorial logic of cardiac gene activation.","evidence":"Cotransfection reporter assays and DNA-binding mutant analysis on the cardiac alpha-actin promoter with Nkx2-5 and SRF","pmids":["11983708"],"confidence":"Medium","gaps":["Physical interaction inferred from functional cooperativity rather than direct Co-IP","Heterologous cell systems only"]},{"year":2004,"claim":"Identified sumoylation as a positive post-translational control of GATA4, showing that a specific modification site and E3 ligase tune both activity and nuclear localization.","evidence":"In vitro sumoylation assay, K366R mutagenesis, and reporter assays identifying PIAS1 as the SUMO E3 ligase","pmids":["15337742"],"confidence":"High","gaps":["Physiological contexts where sumoylation is regulated not defined","Interplay with other PTMs at adjacent residues unaddressed"]},{"year":2010,"claim":"Showed that reversible acetylation gates GATA4's cell-cycle gene program, linking a chromatin-modifying complex to restraint of cardiomyocyte proliferation during development.","evidence":"Co-IP, Hopx/Hdac2 knockout mice, and transactivation assays with interaction domain mapping","pmids":["20833366"],"confidence":"High","gaps":["Specific acetylated lysines not mapped here","Counteracting acetyltransferase not identified in this study"]},{"year":2011,"claim":"Generalized GATA4's pioneer role beyond the heart, demonstrating it opens chromatin and licenses recruitment of nuclear receptors and osteogenic factors in bone.","evidence":"ChIP-seq for GATA4, ERα, and H3K4me2, plus GATA4 knockdown in osteoblasts; ChIP and DNase hypersensitivity at Runx2","pmids":["21566084","30035248"],"confidence":"Medium","gaps":["Single-lab data for each tissue","Mechanism of GATA4 nucleosome engagement not structurally resolved"]},{"year":2014,"claim":"Defined direct GATA4 transcriptional targets and cofactors driving cardiomyocyte proliferation, connecting GATA4/TBX5 cooperativity to cyclin/CDK gene control.","evidence":"Co-IP, ChIP, transactivation assays, lineage-specific knockouts, and Xenopus cardiogenesis for CCND2/CDK4 and Cyclin D2 coactivation","pmids":["24858909","24474767"],"confidence":"High","gaps":["Cyclin D2 acts CDK-independently but the structural basis is unresolved","Relative contributions of GATA4 vs TBX5 at each target not fully separated"]},{"year":2012,"claim":"Distinguished context-dependent functional domains and phosphosites of GATA4, showing that cardiac versus endoderm activities and survival versus cardiogenesis depend on separable residues.","evidence":"Domain deletion and S105 point mutagenesis, BAF60c synergy assays, and Gata4 G295S knock-in mice with proliferation and Ccnd2 analysis","pmids":["22473995","22589735"],"confidence":"Medium","gaps":["Upstream kinase regulating S105 in vivo not pinned down","Tissue-selective hypomorphism mechanism partially explained"]},{"year":2016,"claim":"Mechanistically explained a human congenital heart disease mutation by showing it abolishes GATA4–TBX5 cobinding at super-enhancers and corrupts both activation and repression programs.","evidence":"Patient iPSC-cardiomyocytes with ChIP-seq, ATAC-seq, and functional contractility/calcium assays for GATA4-G296S","pmids":["27984724"],"confidence":"High","gaps":["Allele-specific contributions to each dysregulated gene set not isolated","Therapeutic reversibility untested"]},{"year":2016,"claim":"Established GATA4 as a direct transcriptional repressor in endoderm lineages, restraining hedgehog and alternative fate programs together with GATA6.","evidence":"Conditional Gata4/Gata6 double knockouts with reporter assays mutating GATA sites at the Shh MACS1 enhancer and Dll1 ChIP","pmids":["26932670","24929016"],"confidence":"Medium","gaps":["Corepressor machinery at these elements not defined in these studies","GATA4 versus GATA6 individual contributions overlap"]},{"year":2015,"claim":"Revealed that GATA4 protein stability is a senescence switch, with loss of selective autophagic degradation stabilizing GATA4 to drive inflammatory SASP independent of canonical p53/p16.","evidence":"Genetic LOF, autophagy flux assays, p62 knockdown, ATM/ATR inhibition epistasis, and NF-κB reporters","pmids":["26404840"],"confidence":"High","gaps":["How DNA damage signaling mechanistically blocks p62 recognition of GATA4 not resolved","Direct GATA4 NF-κB target genes not enumerated"]},{"year":2020,"claim":"Expanded the GATA4 degradation network to multiple E3 ligases and proteases, showing CHIP, Parkin, caspase-1, and Rubicon-regulated autophagy converge on GATA4 abundance in disease contexts.","evidence":"Co-IP, ubiquitination assays, in vivo KO/OE for Parkin and CHIP, caspase-1 cleavage with HSP70 protection, and Rubicon Sertoli-specific KO","pmids":["32436607","17525155","25501827","34351902"],"confidence":"Medium","gaps":["Ubiquitin chain types and degron mapping incomplete","Cross-talk between these competing turnover routes not integrated","Mostly single-lab studies per ligase"]},{"year":2022,"claim":"Resolved how a single pioneer factor achieves lineage-specific genome occupancy, showing partner TFs NKX2-5 and ETS1 redirect GATA4 binding and chromatin opening in cardiomyocytes versus endocardium.","evidence":"Lineage-specific biotinylated GATA4 ChIP-seq, ATAC-seq, Co-IP, scRNA-seq, and endothelial Gata4 KO with reporter validation","pmids":["36263775"],"confidence":"High","gaps":["Biophysical basis of ETS1's greater pioneering potency unexplained","Generality to non-cardiac partners untested"]},{"year":2022,"claim":"Connected GATA4 to chromatin-modifying repressor and coactivator complexes and to metabolic/contractile gene partitioning, defining its activating and repressive arms in the heart.","evidence":"Mass spectrometry, Co-IP, ChIP-seq, RNA-seq, and CRISPR silencer deletion for CHD4/NuRD; Co-IP and ChIP-seq for ERRγ/PGC-1α cooperativity","pmids":["35450884","35418170"],"confidence":"High","gaps":["Switch between GATA4-CHD4 repression and GATA4 coactivation not mechanistically defined","How disease mutations selectively impair cooperativity unresolved"]},{"year":2022,"claim":"Linked GATA4 homomultimerization to acetylation-driven activation, providing a structural basis for how p300 acetylation activates GATA4 DNA binding in hypertrophy.","evidence":"Multimerization assays, domain mutagenesis (residues 308-326), acetylation and DNA-binding assays, and cardiomyocyte hypertrophy assays","pmids":["35173540"],"confidence":"Medium","gaps":["Multimer stoichiometry and structure not determined","Single-lab biochemistry"]},{"year":2023,"claim":"Extended GATA4 function to organ identity and physiology in the liver and intestine, showing it specifies endothelial fate, suppresses fibrosis, and gates mucosal immunity.","evidence":"Lineage-specific conditional knockouts with ChIP-seq/ATAC-seq (LSEC, MYC/Pdgfb, EPAS1) and germ-free colonization/infection models with retinol and IgA analysis","pmids":["28218627","32916216","34699385","36630917"],"confidence":"High","gaps":["Whether GATA4 pioneering directly underlies these tissue programs not always tested","Upstream signals controlling GATA4 in these tissues unclear"]},{"year":null,"claim":"How the competing post-translational modifications and degradation pathways are integrated in real time to set GATA4 levels and target selectivity within a given cell remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No unified model coordinating SUMO/acetylation/phosphorylation with autophagic vs proteasomal vs proteolytic turnover","Structural basis of pioneer nucleosome engagement undefined","Direct genome-wide GATA4 target sets in non-cardiac tissues incompletely mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[3,4,8,11,13,19,34]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[5,14,22,29,39,42]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,27]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[3,13]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,4,13]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[8,15,18,34]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[11,16,20,21]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[0]}],"complexes":["CHD4/NuRD repressor complex"],"partners":["TBX5","NKX2-5","ETS1","SRF","CHD4","CCND2","ESRRG","STAT1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P43694","full_name":"Transcription factor GATA-4","aliases":["GATA-binding factor 4"],"length_aa":442,"mass_kda":44.6,"function":"Transcriptional activator that binds to the consensus sequence 5'-AGATAG-3' and plays a key role in cardiac development and function (PubMed:24000169, PubMed:27984724, PubMed:35182466). In cooperation with TBX5, it binds to cardiac super-enhancers and promotes cardiomyocyte gene expression, while it down-regulates endocardial and endothelial gene expression (PubMed:27984724). Involved in bone morphogenetic protein (BMP)-mediated induction of cardiac-specific gene expression. Binds to BMP response element (BMPRE) DNA sequences within cardiac activating regions (By similarity). Acts as a transcriptional activator of ANF in cooperation with NKX2-5 (By similarity). Promotes cardiac myocyte enlargement (PubMed:20081228). Required during testicular development (PubMed:21220346). May play a role in sphingolipid signaling by regulating the expression of sphingosine-1-phosphate degrading enzyme, sphingosine-1-phosphate lyase (PubMed:15734735)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P43694/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GATA4","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CANX","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/GATA4","total_profiled":1310},"omim":[{"mim_id":"620057","title":"PHD FINGER PROTEIN 7; PHF7","url":"https://www.omim.org/entry/620057"},{"mim_id":"619820","title":"ATONAL bHLH TRANSCRIPTION FACTOR 8; ATOH8","url":"https://www.omim.org/entry/619820"},{"mim_id":"619463","title":"PORTAL HYPERTENSION, NONCIRRHOTIC, 2; NCPH2","url":"https://www.omim.org/entry/619463"},{"mim_id":"617912","title":"CONGENITAL HEART DEFECTS, MULTIPLE TYPES, 5; CHTD5","url":"https://www.omim.org/entry/617912"},{"mim_id":"616067","title":"46,XY SEX REVERSAL 9; SRXY9","url":"https://www.omim.org/entry/616067"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nuclear bodies","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"heart muscle","ntpm":80.1},{"tissue":"ovary","ntpm":85.2},{"tissue":"pancreas","ntpm":48.3}],"url":"https://www.proteinatlas.org/search/GATA4"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P43694","domains":[{"cath_id":"3.30.50.10","chopping":"212-259","consensus_level":"medium","plddt":88.7531,"start":212,"end":259},{"cath_id":"3.30.50.10","chopping":"268-311","consensus_level":"medium","plddt":95.628,"start":268,"end":311}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P43694","model_url":"https://alphafold.ebi.ac.uk/files/AF-P43694-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P43694-F1-predicted_aligned_error_v6.png","plddt_mean":57.22},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GATA4","jax_strain_url":"https://www.jax.org/strain/search?query=GATA4"},"sequence":{"accession":"P43694","fasta_url":"https://rest.uniprot.org/uniprotkb/P43694.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P43694/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P43694"}},"corpus_meta":[{"pmid":"26404840","id":"PMC_26404840","title":"The DNA damage response induces inflammation and senescence by inhibiting autophagy of GATA4.","date":"2015","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/26404840","citation_count":790,"is_preprint":false},{"pmid":"15310850","id":"PMC_15310850","title":"GATA4 is essential for formation of the proepicardium and regulates cardiogenesis.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15310850","citation_count":287,"is_preprint":false},{"pmid":"19901028","id":"PMC_19901028","title":"Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19901028","citation_count":246,"is_preprint":false},{"pmid":"27984724","id":"PMC_27984724","title":"Disease Model of GATA4 Mutation Reveals Transcription Factor Cooperativity in Human Cardiogenesis.","date":"2016","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/27984724","citation_count":225,"is_preprint":false},{"pmid":"17643447","id":"PMC_17643447","title":"Spectrum of heart disease associated with murine and human GATA4 mutation.","date":"2007","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/17643447","citation_count":197,"is_preprint":false},{"pmid":"25416133","id":"PMC_25416133","title":"Stoichiometry of Gata4, Mef2c, and Tbx5 influences the efficiency and quality of induced cardiac myocyte reprogramming.","date":"2014","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/25416133","citation_count":194,"is_preprint":false},{"pmid":"9231805","id":"PMC_9231805","title":"Expression and hormonal regulation of transcription factors GATA-4 and GATA-6 in the mouse ovary.","date":"1997","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9231805","citation_count":179,"is_preprint":false},{"pmid":"16079152","id":"PMC_16079152","title":"Gata4 regulates the formation of multiple organs.","date":"2005","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16079152","citation_count":171,"is_preprint":false},{"pmid":"10067876","id":"PMC_10067876","title":"Expression and regulation of transcription factors GATA-4 and GATA-6 in developing mouse testis.","date":"1999","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/10067876","citation_count":169,"is_preprint":false},{"pmid":"16847256","id":"PMC_16847256","title":"A threshold of GATA4 and GATA6 expression is required for cardiovascular development.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16847256","citation_count":166,"is_preprint":false},{"pmid":"19509152","id":"PMC_19509152","title":"GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer.","date":"2009","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/19509152","citation_count":164,"is_preprint":false},{"pmid":"15810002","id":"PMC_15810002","title":"Phenotypes with GATA4 or NKX2.5 mutations in familial atrial septal defect.","date":"2005","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/15810002","citation_count":164,"is_preprint":false},{"pmid":"16470721","id":"PMC_16470721","title":"A novel mutation in the GATA4 gene in patients with Tetralogy of Fallot.","date":"2006","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/16470721","citation_count":131,"is_preprint":false},{"pmid":"32916216","id":"PMC_32916216","title":"Endothelial GATA4 controls liver fibrosis and regeneration by preventing a pathogenic switch in angiocrine signaling.","date":"2020","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/32916216","citation_count":130,"is_preprint":false},{"pmid":"11983708","id":"PMC_11983708","title":"Combinatorial expression of GATA4, Nkx2-5, and serum response factor directs early cardiac gene activity.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11983708","citation_count":128,"is_preprint":false},{"pmid":"20833366","id":"PMC_20833366","title":"Hopx and Hdac2 interact to modulate Gata4 acetylation and embryonic cardiac myocyte proliferation.","date":"2010","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/20833366","citation_count":125,"is_preprint":false},{"pmid":"23006330","id":"PMC_23006330","title":"GATA4 and GATA6 control mouse pancreas organogenesis.","date":"2012","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/23006330","citation_count":125,"is_preprint":false},{"pmid":"28218627","id":"PMC_28218627","title":"GATA4-dependent organ-specific endothelial differentiation controls liver development and embryonic hematopoiesis.","date":"2017","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/28218627","citation_count":120,"is_preprint":false},{"pmid":"24696446","id":"PMC_24696446","title":"GATA4 mutations are a cause of neonatal and childhood-onset diabetes.","date":"2014","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/24696446","citation_count":104,"is_preprint":false},{"pmid":"21172404","id":"PMC_21172404","title":"GATA4 regulates Sertoli cell function and fertility in adult male mice.","date":"2010","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21172404","citation_count":96,"is_preprint":false},{"pmid":"28541271","id":"PMC_28541271","title":"Protein-altering and regulatory genetic variants near GATA4 implicated in bicuspid aortic valve.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28541271","citation_count":91,"is_preprint":false},{"pmid":"21839733","id":"PMC_21839733","title":"GATA5 interacts with GATA4 and GATA6 in outflow tract development.","date":"2011","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/21839733","citation_count":87,"is_preprint":false},{"pmid":"22449843","id":"PMC_22449843","title":"Regulation of GATA4 transcriptional activity in cardiovascular development and disease.","date":"2012","source":"Current topics in developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/22449843","citation_count":85,"is_preprint":false},{"pmid":"15337742","id":"PMC_15337742","title":"SUMO-1 modification activated GATA4-dependent cardiogenic gene activity.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15337742","citation_count":85,"is_preprint":false},{"pmid":"14583613","id":"PMC_14583613","title":"Hepatic erythropoietin gene regulation by GATA-4.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14583613","citation_count":76,"is_preprint":false},{"pmid":"22589735","id":"PMC_22589735","title":"Congenital heart disease-causing Gata4 mutation displays functional deficits in vivo.","date":"2012","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22589735","citation_count":76,"is_preprint":false},{"pmid":"19850025","id":"PMC_19850025","title":"Gata4 directs development of cardiac-inducing endoderm from ES cells.","date":"2009","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/19850025","citation_count":63,"is_preprint":false},{"pmid":"24929016","id":"PMC_24929016","title":"GATA4 and GATA6 regulate intestinal epithelial cytodifferentiation during development.","date":"2014","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/24929016","citation_count":62,"is_preprint":false},{"pmid":"26932670","id":"PMC_26932670","title":"GATA4 and GATA6 regulate pancreatic endoderm identity through inhibition of hedgehog signaling.","date":"2016","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/26932670","citation_count":59,"is_preprint":false},{"pmid":"17142311","id":"PMC_17142311","title":"Gata4 is necessary for normal pulmonary lobar development.","date":"2006","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17142311","citation_count":59,"is_preprint":false},{"pmid":"16260600","id":"PMC_16260600","title":"Convergence of protein kinase C and JAK-STAT signaling on transcription factor GATA-4.","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16260600","citation_count":56,"is_preprint":false},{"pmid":"28167794","id":"PMC_28167794","title":"Gata4 potentiates second heart field proliferation and Hedgehog signaling for cardiac septation.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28167794","citation_count":56,"is_preprint":false},{"pmid":"21566084","id":"PMC_21566084","title":"GATA4 regulates estrogen receptor-alpha-mediated osteoblast transcription.","date":"2011","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/21566084","citation_count":52,"is_preprint":false},{"pmid":"24858909","id":"PMC_24858909","title":"Disruption of myocardial Gata4 and Tbx5 results in defects in cardiomyocyte proliferation and atrioventricular septation.","date":"2014","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24858909","citation_count":52,"is_preprint":false},{"pmid":"22552926","id":"PMC_22552926","title":"Mutation spectrum of the GATA4 gene in patients with idiopathic atrial fibrillation.","date":"2012","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/22552926","citation_count":49,"is_preprint":false},{"pmid":"24182332","id":"PMC_24182332","title":"DNA methylation status of NKX2-5, GATA4 and HAND1 in patients with tetralogy of fallot.","date":"2013","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/24182332","citation_count":49,"is_preprint":false},{"pmid":"26974005","id":"PMC_26974005","title":"GATA4 Regulates Blood-Testis Barrier Function and Lactate Metabolism in Mouse Sertoli Cells.","date":"2016","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/26974005","citation_count":49,"is_preprint":false},{"pmid":"31710289","id":"PMC_31710289","title":"Induction of Sertoli-like cells from human fibroblasts by NR5A1 and GATA4.","date":"2019","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/31710289","citation_count":47,"is_preprint":false},{"pmid":"29717129","id":"PMC_29717129","title":"GATA4 regulates angiogenesis and persistence of inflammation in rheumatoid arthritis.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29717129","citation_count":46,"is_preprint":false},{"pmid":"14761664","id":"PMC_14761664","title":"Regulation of cardiac myocyte apoptosis by the GATA-4 transcription factor.","date":"2004","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/14761664","citation_count":46,"is_preprint":false},{"pmid":"21248289","id":"PMC_21248289","title":"GATA4 deficiency impairs ovarian function in adult mice.","date":"2011","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/21248289","citation_count":46,"is_preprint":false},{"pmid":"29325903","id":"PMC_29325903","title":"GATA4 Loss-of-Function Mutation and the Congenitally Bicuspid Aortic Valve.","date":"2017","source":"The American journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/29325903","citation_count":43,"is_preprint":false},{"pmid":"27066525","id":"PMC_27066525","title":"GATA4 regulates epithelial cell proliferation to control intestinal growth and development in mice.","date":"2016","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/27066525","citation_count":43,"is_preprint":false},{"pmid":"17525155","id":"PMC_17525155","title":"Diminished GATA4 protein levels contribute to hyperglycemia-induced cardiomyocyte injury.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17525155","citation_count":43,"is_preprint":false},{"pmid":"24041700","id":"PMC_24041700","title":"GATA4 loss-of-function mutation underlies familial dilated cardiomyopathy.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/24041700","citation_count":41,"is_preprint":false},{"pmid":"34699385","id":"PMC_34699385","title":"GATA4 induces liver fibrosis regression by deactivating hepatic stellate cells.","date":"2021","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/34699385","citation_count":40,"is_preprint":false},{"pmid":"33876316","id":"PMC_33876316","title":"Fibroblast GATA-4 and GATA-6 promote myocardial adaptation to pressure overload by enhancing cardiac angiogenesis.","date":"2021","source":"Basic research in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/33876316","citation_count":40,"is_preprint":false},{"pmid":"35418170","id":"PMC_35418170","title":"The nuclear receptor ERR cooperates with the cardiogenic factor GATA4 to orchestrate cardiomyocyte maturation.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35418170","citation_count":39,"is_preprint":false},{"pmid":"24932701","id":"PMC_24932701","title":"GATA4 is essential for bone mineralization via ERα and TGFβ/BMP pathways.","date":"2014","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/24932701","citation_count":39,"is_preprint":false},{"pmid":"35563646","id":"PMC_35563646","title":"Towards Understanding the Gene-Specific Roles of GATA Factors in Heart Development: Does GATA4 Lead the Way?","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35563646","citation_count":38,"is_preprint":false},{"pmid":"35275720","id":"PMC_35275720","title":"GATA4/5/6 family transcription factors are conserved determinants of cardiac versus pharyngeal mesoderm fate.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/35275720","citation_count":37,"is_preprint":false},{"pmid":"35450884","id":"PMC_35450884","title":"CHD4 is recruited by GATA4 and NKX2-5 to repress noncardiac gene programs in the developing heart.","date":"2022","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/35450884","citation_count":36,"is_preprint":false},{"pmid":"25017055","id":"PMC_25017055","title":"Prevalence and spectrum of GATA4 mutations associated with sporadic dilated cardiomyopathy.","date":"2014","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/25017055","citation_count":35,"is_preprint":false},{"pmid":"24366163","id":"PMC_24366163","title":"A novel GATA4 loss-of-function mutation responsible for familial dilated cardiomyopathy.","date":"2013","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24366163","citation_count":35,"is_preprint":false},{"pmid":"17337116","id":"PMC_17337116","title":"Adrenocortical tumorigenesis, luteinizing hormone receptor and transcription factors GATA-4 and GATA-6.","date":"2007","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17337116","citation_count":33,"is_preprint":false},{"pmid":"29545582","id":"PMC_29545582","title":"Cardiac Actions of a Small Molecule Inhibitor Targeting GATA4-NKX2-5 Interaction.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29545582","citation_count":33,"is_preprint":false},{"pmid":"32436607","id":"PMC_32436607","title":"Parkin ubiquitinates GATA4 and attenuates the GATA4/GAS1 signaling and detrimental effects on diabetic nephropathy.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/32436607","citation_count":32,"is_preprint":false},{"pmid":"26183893","id":"PMC_26183893","title":"Notch signaling represses GATA4-induced expression of genes involved in steroid biosynthesis.","date":"2015","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/26183893","citation_count":32,"is_preprint":false},{"pmid":"34373748","id":"PMC_34373748","title":"GATA4-driven miR-206-3p signatures control orofacial bone development by regulating osteogenic and osteoclastic activity.","date":"2021","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/34373748","citation_count":32,"is_preprint":false},{"pmid":"31419020","id":"PMC_31419020","title":"Targeting GATA4 for cardiac repair.","date":"2019","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/31419020","citation_count":31,"is_preprint":false},{"pmid":"35941043","id":"PMC_35941043","title":"The NOTCH4-GATA4-IRG1 axis as a novel target in early-onset colorectal cancer.","date":"2022","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/35941043","citation_count":31,"is_preprint":false},{"pmid":"25501827","id":"PMC_25501827","title":"Caspase-1 cleavage of transcription factor GATA4 and regulation of cardiac cell fate.","date":"2014","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/25501827","citation_count":31,"is_preprint":false},{"pmid":"20554787","id":"PMC_20554787","title":"GATA4 protects granulosa cell tumors from TRAIL-induced apoptosis.","date":"2010","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20554787","citation_count":31,"is_preprint":false},{"pmid":"26376067","id":"PMC_26376067","title":"A novel mutation of GATA4 (K300T) associated with familial atrial septal defect.","date":"2015","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/26376067","citation_count":31,"is_preprint":false},{"pmid":"29155983","id":"PMC_29155983","title":"Meox1 accelerates myocardial hypertrophic decompensation through Gata4.","date":"2018","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/29155983","citation_count":30,"is_preprint":false},{"pmid":"20874724","id":"PMC_20874724","title":"GATA4 regulates ANF expression synergistically with Sp1 in a cardiac hypertrophy model.","date":"2011","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20874724","citation_count":29,"is_preprint":false},{"pmid":"24474767","id":"PMC_24474767","title":"Cyclin D2 is a GATA4 cofactor in cardiogenesis.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24474767","citation_count":28,"is_preprint":false},{"pmid":"30142155","id":"PMC_30142155","title":"RETRACTED: GATA4 inhibits cell differentiation and proliferation in pancreatic cancer.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30142155","citation_count":27,"is_preprint":false},{"pmid":"36263775","id":"PMC_36263775","title":"GATA4 Regulates Developing Endocardium Through Interaction With ETS1.","date":"2022","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/36263775","citation_count":27,"is_preprint":false},{"pmid":"20347099","id":"PMC_20347099","title":"A novel mutation in GATA4 gene associated with dominant inherited familial atrial septal defect.","date":"2010","source":"The Journal of thoracic and cardiovascular surgery","url":"https://pubmed.ncbi.nlm.nih.gov/20347099","citation_count":27,"is_preprint":false},{"pmid":"17272516","id":"PMC_17272516","title":"Gata4 and Hnf1alpha are partially required for the expression of specific intestinal genes during development.","date":"2007","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17272516","citation_count":27,"is_preprint":false},{"pmid":"19302747","id":"PMC_19302747","title":"GATA4 and NKX2.5 gene analysis in Chinese Uygur patients with congenital heart disease.","date":"2009","source":"Chinese medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/19302747","citation_count":27,"is_preprint":false},{"pmid":"36630917","id":"PMC_36630917","title":"GATA4 controls regionalization of tissue immunity and commensal-driven immunopathology.","date":"2023","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/36630917","citation_count":26,"is_preprint":false},{"pmid":"36322626","id":"PMC_36322626","title":"TRIM35-mediated degradation of nuclear PKM2 destabilizes GATA4/6 and induces P53 in cardiomyocytes to promote heart failure.","date":"2022","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36322626","citation_count":26,"is_preprint":false},{"pmid":"24866383","id":"PMC_24866383","title":"NEXN inhibits GATA4 and leads to atrial septal defects in mice and humans.","date":"2014","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/24866383","citation_count":26,"is_preprint":false},{"pmid":"23751912","id":"PMC_23751912","title":"Lrrc10 is a novel cardiac-specific target gene of Nkx2-5 and GATA4.","date":"2013","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/23751912","citation_count":26,"is_preprint":false},{"pmid":"30035248","id":"PMC_30035248","title":"GATA4 Directly Regulates Runx2 Expression and Osteoblast Differentiation.","date":"2017","source":"JBMR plus","url":"https://pubmed.ncbi.nlm.nih.gov/30035248","citation_count":25,"is_preprint":false},{"pmid":"22473995","id":"PMC_22473995","title":"Dissociation of cardiogenic and postnatal myocardial activities of GATA4.","date":"2012","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22473995","citation_count":25,"is_preprint":false},{"pmid":"28484278","id":"PMC_28484278","title":"Role of GATA binding protein 4 (GATA4) in the regulation of tooth development via GNAI3.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28484278","citation_count":25,"is_preprint":false},{"pmid":"28393293","id":"PMC_28393293","title":"GATA4 regulates osteoblastic differentiation and bone remodeling via p38-mediated signaling.","date":"2017","source":"Journal of molecular histology","url":"https://pubmed.ncbi.nlm.nih.gov/28393293","citation_count":24,"is_preprint":false},{"pmid":"25933105","id":"PMC_25933105","title":"Adrenal Development in Mice Requires GATA4 and GATA6 Transcription Factors.","date":"2015","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/25933105","citation_count":24,"is_preprint":false},{"pmid":"31628386","id":"PMC_31628386","title":"Stoichiometric optimization of Gata4, Hand2, Mef2c, and Tbx5 expression for contractile cardiomyocyte reprogramming.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31628386","citation_count":23,"is_preprint":false},{"pmid":"28471988","id":"PMC_28471988","title":"Associations of GATA4 genetic mutations with the risk of congenital heart disease: A meta-analysis.","date":"2017","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28471988","citation_count":23,"is_preprint":false},{"pmid":"29445146","id":"PMC_29445146","title":"Dural effects of oxidative stress on cardiomyogenesis via Gata4 transcription and protein ubiquitination.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29445146","citation_count":23,"is_preprint":false},{"pmid":"31767831","id":"PMC_31767831","title":"Kindlin-2 suppresses transcription factor GATA4 through interaction with SUV39H1 to attenuate hypertrophy.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31767831","citation_count":23,"is_preprint":false},{"pmid":"34351902","id":"PMC_34351902","title":"Rubicon prevents autophagic degradation of GATA4 to promote Sertoli cell function.","date":"2021","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34351902","citation_count":22,"is_preprint":false},{"pmid":"31120883","id":"PMC_31120883","title":"Gata4 regulates hedgehog signaling and Gata6 expression for outflow tract development.","date":"2019","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31120883","citation_count":21,"is_preprint":false},{"pmid":"28111280","id":"PMC_28111280","title":"Inhibition of Gata4 and Tbx5 by Nicotine-Mediated DNA Methylation in Myocardial Differentiation.","date":"2017","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/28111280","citation_count":21,"is_preprint":false},{"pmid":"26687508","id":"PMC_26687508","title":"Unique functions of Gata4 in mouse liver induction and heart development.","date":"2015","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/26687508","citation_count":21,"is_preprint":false},{"pmid":"35017504","id":"PMC_35017504","title":"A GATA4-regulated secretory program suppresses tumors through recruitment of cytotoxic CD8 T cells.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35017504","citation_count":20,"is_preprint":false},{"pmid":"21609320","id":"PMC_21609320","title":"GATA-4 transcription factor regulates hepatic hepcidin expression.","date":"2011","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/21609320","citation_count":19,"is_preprint":false},{"pmid":"22461617","id":"PMC_22461617","title":"GATA4 is a critical regulator of gonadectomy-induced adrenocortical tumorigenesis in mice.","date":"2012","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/22461617","citation_count":19,"is_preprint":false},{"pmid":"36804620","id":"PMC_36804620","title":"Oncogenic SIRT7 inhibits GATA4 transcriptional activity and activates the Wnt signaling pathway in ovarian cancer.","date":"2023","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36804620","citation_count":18,"is_preprint":false},{"pmid":"21029371","id":"PMC_21029371","title":"Gata4 and Sp1 regulate expression of the erythropoietin receptor in cardiomyocytes.","date":"2011","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21029371","citation_count":18,"is_preprint":false},{"pmid":"35173540","id":"PMC_35173540","title":"Multimerization of the GATA4 transcription factor regulates transcriptional activity and cardiomyocyte hypertrophic response.","date":"2022","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35173540","citation_count":18,"is_preprint":false},{"pmid":"27788486","id":"PMC_27788486","title":"GATA4 promotes hepatoblastoma cell proliferation by altering expression of miR125b and DKK3.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27788486","citation_count":17,"is_preprint":false},{"pmid":"17559079","id":"PMC_17559079","title":"Induction of Id2 expression by cardiac transcription factors GATA4 and Nkx2.5.","date":"2008","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17559079","citation_count":17,"is_preprint":false},{"pmid":"30306767","id":"PMC_30306767","title":"GATA4 is a negative regulator of contractility in mouse testicular peritubular myoid cells.","date":"2018","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/30306767","citation_count":17,"is_preprint":false},{"pmid":"22923619","id":"PMC_22923619","title":"Cyclin D2 rescues size and function of GATA4 haplo-insufficient hearts.","date":"2012","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22923619","citation_count":17,"is_preprint":false},{"pmid":"36177479","id":"PMC_36177479","title":"DNA damage response and GATA4 signaling in cellular senescence and aging-related pathology.","date":"2022","source":"Frontiers in aging neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/36177479","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51040,"output_tokens":12270,"usd":0.168585,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":23387,"output_tokens":5157,"usd":0.12293,"stage2_stop_reason":"end_turn"},"total_usd":0.291515,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2015,\n      \"finding\": \"GATA4 is normally degraded by p62-mediated selective autophagy; during senescence, this autophagic degradation is suppressed, stabilizing GATA4. Stabilized GATA4 then activates NF-κB to initiate the senescence-associated secretory phenotype (SASP). GATA4 activation in this context depends on the DNA damage response kinases ATM and ATR, but not on p53 or p16(INK4a).\",\n      \"method\": \"Genetic loss-of-function, protein stability assays, autophagy flux assays, epistasis experiments with ATM/ATR inhibitors and p62 knockdown, NF-κB reporter assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (genetic KD, pharmacologic inhibition, epistasis, reporter assays) in a high-profile study; mechanistic pathway clearly delineated\",\n      \"pmids\": [\"26404840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"GATA4 is sumoylated by SUMO-1 at lysine 366, which enhances its transcriptional activity. PIAS1 acts as the E3 SUMO ligase for GATA4 through its RING finger domain. Mutation of K366R reduces GATA4 nuclear occupancy, suggesting SUMO modification also modulates nuclear localization.\",\n      \"method\": \"In vitro sumoylation assay, site-directed mutagenesis (K366R), co-transfection reporter assays, subcellular localization analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro sumoylation assay plus mutagenesis plus functional reporter assays in a single study; modification site and E3 ligase both identified\",\n      \"pmids\": [\"15337742\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Hdac2 physically interacts with GATA4 and mediates its deacetylation; this interaction is stabilized by the homeodomain factor Hopx. Hopx/Hdac2-mediated deacetylation of GATA4 impairs its ability to transactivate cell cycle genes, restraining cardiomyocyte proliferation during embryonic development. Loss of Hopx and Hdac2 leads to GATA4 hyperacetylation, increased cardiomyocyte proliferation, and upregulation of GATA4 target genes.\",\n      \"method\": \"Co-immunoprecipitation, genetic knockout (Hopx and Hdac2 null mice), cardiomyocyte proliferation assays, transactivation assays, interaction domain mapping\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — Co-IP plus in vivo genetic models plus functional transactivation assays; multiple orthogonal approaches in a single study\",\n      \"pmids\": [\"20833366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The GATA4-G296S disease-causing missense mutation disrupts physical interaction with TBX5, particularly at cardiac super-enhancers, leading to failure of TBX5 recruitment and dysregulation of cardiac septation genes. The mutation also causes failure of GATA4/TBX5-mediated repression at non-cardiac genes and aberrant chromatin opening at endothelial/endocardial promoters.\",\n      \"method\": \"iPS-derived cardiomyocytes from patients, ChIP-seq, ATAC-seq, co-occupancy analysis, functional contractility and calcium handling assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — human disease iPSC model with genome-wide chromatin occupancy and functional assays; multiple orthogonal methods in a high-impact study\",\n      \"pmids\": [\"27984724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"GATA4, Nkx2-5, and SRF form higher-order complexes on the cardiac alpha-actin (alphaCA) promoter and synergistically activate its transcription. SRF DNA binding is required to recruit Nkx2-5 and GATA4 to the promoter, and their recruitment enhances SRF DNA-binding affinity. A DNA-binding-defective Nkx2-5 mutant retains coactivation activity in the presence of SRF and GATA4.\",\n      \"method\": \"Cotransfection reporter assays in CV1 fibroblasts and Schneider 2 cells, embryonic stem cell endogenous gene induction, DNA-binding mutant analysis, promoter deletion/mutation analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple reporter and mutant analyses in heterologous systems; physical interaction inferred from functional cooperativity and mutant data but direct Co-IP not reported in abstract\",\n      \"pmids\": [\"11983708\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PKC phosphorylation of GATA4 enhances its DNA-binding activity. STAT-1 physically interacts with GATA4 and synergistically activates ANF and other growth factor-inducible promoters. GATA factors can recruit STAT proteins to target promoters via GATA binding sites, enabling STAT proteins to act as growth factor-inducible coactivators of tissue-specific transcription.\",\n      \"method\": \"Co-immunoprecipitation, luciferase reporter assays, EMSA (DNA-binding activity), PKC inhibitor/activator treatments, STAT binding site mutations\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP and reporter assays; multiple methods in one lab but replication not established\",\n      \"pmids\": [\"16260600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Cyclin D2 (CycD2) physically interacts with GATA4 through a discrete N-terminal activation domain (aa 129-152) and acts as a CDK-independent coactivator, synergistically enhancing GATA-dependent transcription. GATA4 recruits CycD2 to its target promoters. Human congenital heart disease mutations in this domain disrupt CycD2-GATA4 synergy. CycD1 does not potentiate GATA4 activity.\",\n      \"method\": \"Co-immunoprecipitation, ChIP, luciferase reporter assays, domain deletion/mutation analysis, Xenopus embryo cardiogenesis assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — Co-IP plus ChIP plus reporter assays plus in vivo Xenopus validation; multiple orthogonal methods in one study\",\n      \"pmids\": [\"24474767\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The N-terminal domain of GATA4 (aa 129–152) is required for cardiogenic activity and for transcriptional synergy with BAF60c. A serine at position 105 (S105, a known MAPK phosphorylation target) is required for GATA4-dependent cardiomyocyte survival and hypertrophy but dispensable for cardiogenesis. S105 is differentially required for transcriptional synergy with SRF but not TBX5 or NKX2.5.\",\n      \"method\": \"Domain deletion and point mutagenesis, luciferase reporter assays, cardiomyocyte survival assays, Xenopus embryo cardiogenesis assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro mutagenesis combined with in vivo Xenopus assays; dissection of distinct functional domains\",\n      \"pmids\": [\"22473995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GATA4 and TBX5 co-localize and physically interact in the developing atria and ventricles (demonstrated by co-immunoprecipitation). Gata4 and Tbx5 cooperatively and directly regulate Cdk4 transcription (by ChIP and transactivation assays), while only Tbx5 activates Cdk2. Loss of myocardial GATA4 combined with Tbx5 heterozygosity (but not endocardial GATA4 loss) causes thin myocardium, reduced cardiomyocyte proliferation, and atrioventricular septation defects.\",\n      \"method\": \"Co-immunoprecipitation, co-localization, ChIP, luciferase transactivation assays, conditional Cre-loxP knockout (myocardial vs endocardial lineages)\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — reciprocal Co-IP, ChIP, transactivation, and lineage-specific in vivo genetics; multiple orthogonal methods\",\n      \"pmids\": [\"24858909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CHIP (carboxyl terminus of Hsp70-interacting protein), an E3 ubiquitin ligase, promotes GATA4 protein degradation via the ubiquitin-proteasome system. High glucose increases CHIP mRNA expression, leading to increased GATA4 protein degradation; proteasome inhibition reverses this. CHIP knockdown prevents high glucose-induced GATA4 depletion.\",\n      \"method\": \"Proteasome inhibitor treatment, CHIP overexpression and siRNA knockdown, UPS reporter assay, western blotting, in vivo diabetic mouse models\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function for CHIP plus pharmacologic inhibition plus in vivo validation; single lab\",\n      \"pmids\": [\"17525155\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Caspase-1 cleaves GATA4 both in vivo and in vitro, generating a truncated protein that retains DNA binding ability but lacks transcriptional activation domains and acts as a dominant-negative regulator of GATA4. Caspase-1 is rapidly activated in cardiomyocyte nuclei upon doxorubicin treatment. Inhibition of caspase-1 alone is sufficient to rescue GATA4 degradation and cardiomyocyte death. HSP70 binds directly to GATA4 and masks the caspase recognition motif, protecting it from cleavage.\",\n      \"method\": \"In vitro caspase-1 cleavage assay, dominant-negative mutant analysis, cardiomyocyte cell death assays, caspase-1 inhibition, Co-immunoprecipitation (HSP70-GATA4)\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro cleavage assay plus dominant-negative functional analysis plus Co-IP; multiple orthogonal methods in a single study\",\n      \"pmids\": [\"25501827\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CHD4 (catalytic subunit of NuRD complex) physically interacts with GATA4, NKX2-5, and TBX5 during embryonic heart development (demonstrated by mass spectrometry and co-IP). GATA4-CHD4 complexes occupy and repress specific cardiac gene targets, including silencers of skeletal muscle (Acta1) and smooth muscle (Myh11) genes in the embryonic heart; deletion of these silencers leads to inappropriate misexpression of these genes in the heart.\",\n      \"method\": \"Mass spectrometry, co-immunoprecipitation, ChIP-seq, RNA-seq, in vivo CRISPR/Cas9 silencer deletion\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — MS-based protein interaction, Co-IP, genome-wide occupancy, and in vivo genetic validation of specific enhancers/silencers; multiple orthogonal methods\",\n      \"pmids\": [\"35450884\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ERRγ interacts physically with GATA4 to cooperatively activate transcription of cardiomyocyte-specific contractile genes (but not metabolic genes, which require PGC-1α independently of GATA4). ERRγ and GATA4 co-occupy cardiac enhancers/super-enhancers genome-wide. A disease-causing GATA4 mutation diminishes PGC-1α/ERR/GATA4 cooperativity.\",\n      \"method\": \"Co-immunoprecipitation, ChIP-seq, hiPSC-CM differentiation, luciferase reporter assays, disease mutation functional analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and genome-wide ChIP-seq plus reporter assays; single lab, multiple methods\",\n      \"pmids\": [\"35418170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GATA4 functions as a pioneer transcription factor whose lineage-specific chromatin occupancy is directed by co-expressed non-pioneer transcription factors: NKX2-5 in cardiomyocytes and ETS1 in endocardial cells. Both NKX2-5 and ETS1 physically interact with GATA4 (by Co-IP) and re-direct its pioneer binding genome-wide, augmenting chromatin opening. ETS1 displays greater potency than NKX2-5 as a pioneer partner. GATA4 and ETS1 cooperatively stimulate endothelial cell enhancer activity.\",\n      \"method\": \"Lineage-specific Cre-activated GATA4 biotinylation followed by ChIP-seq, ATAC-seq, co-immunoprecipitation, scRNA-seq, luciferase reporter assays, conditional endothelial Gata4 knockout\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — lineage-specific genome-wide occupancy, ATAC-seq, Co-IP, scRNA-seq, and in vivo KO with reporter validation; comprehensive mechanistic dissection\",\n      \"pmids\": [\"36263775\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GATA4 forms a homomultimer; residues 308–326 are necessary for multimerization. Acetylation of GATA4 by p300 induces its multimerization and activates DNA-binding activity. Suppression of GATA4 multimerization represses GATA4/p300-induced gene transcription and inhibits phenylephrine-induced hypertrophic response in cardiomyocytes without reducing acetylation.\",\n      \"method\": \"Protein multimerization assays, domain mutagenesis, acetylation assays, DNA-binding activity measurement, cardiomyocyte hypertrophy assays\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical multimerization assays plus mutagenesis plus functional hypertrophy assays; single lab\",\n      \"pmids\": [\"35173540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GATA4 controls liver sinusoidal endothelial cell (LSEC) specification; its deletion causes transformation of discontinuous liver sinusoids into continuous capillaries, characterized by ectopic basement membrane deposition, continuous EC layer formation, and increased VE-cadherin expression. Ectopic GATA4 expression in continuous ECs downregulates continuous EC transcripts and upregulates LSEC-associated genes.\",\n      \"method\": \"LSEC-specific conditional Gata4 knockout (Cre-loxP), GATA4 overexpression in cultured ECs, histology, electron microscopy, transcriptomic profiling\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — lineage-specific in vivo KO plus gain-of-function in cultured cells plus structural validation; replicated in subsequent paper (PMID 32916216)\",\n      \"pmids\": [\"28218627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In adult LSECs, GATA4 loss triggers a profibrotic angiocrine switch involving de novo endothelial expression of PDGFB (a hepatic stellate cell-activating cytokine). MYC activation mediates ectopic Pdgfb expression by increasing chromatin accessibility at the Pdgfb locus, downstream of GATA4 loss. GATA4 thus protects against perisinusoidal liver fibrosis by repressing MYC activation and profibrotic angiocrine signaling at the chromatin level.\",\n      \"method\": \"LSEC-specific adult Gata4 conditional KO, ChIP-seq, ATAC-seq, gene expression profiling, dietary and chemical fibrosis models, human scRNA-seq datasets\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — conditional in vivo KO with chromatin-level mechanistic data (ChIP-seq, ATAC-seq) plus multiple fibrosis models plus human data\",\n      \"pmids\": [\"32916216\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GATA4 directly represses EPAS1 (encoding HIF2α) transcription in hepatic stellate cells. Overexpression of GATA4 in hepatic stellate cells promotes liver fibrosis regression (deactivation); lack of GATA4 in adult mice causes hepatic stellate cell activation and liver fibrosis. Stabilization of HIF2α in hepatic stellate cells leads to liver fibrosis.\",\n      \"method\": \"Conditional Gata4 knockout in mice, adenoviral Gata4 overexpression, CCl4 fibrosis model, ChIP for GATA4 at EPAS1 promoter, HIF2α stabilization experiments\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo KO and OE plus ChIP validation of direct EPAS1 repression; single lab\",\n      \"pmids\": [\"34699385\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GATA4 directly activates a cis-regulatory element at Gli1 in vitro (luciferase assay) and occupies this element in vivo (ChIP), placing Gata4 directly upstream of Hedgehog signaling components in the second heart field. Gata4 haploinsufficiency in the SHF causes Hedgehog signaling defects; constitutive SHF Hh signaling activation rescues AVSDs in Gata4 SHF-specific heterozygotes. A parallel cell-cycle defect (via PTEN/cell cycle) acts independently of Hh.\",\n      \"method\": \"SHF-specific conditional Gata4 heterozygote mice, luciferase reporter assay (Gli1 cis-element), ChIP (Gata4 at Gli1 element), Pten knockdown rescue, constitutive Smo activation rescue\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct target identification (luciferase + ChIP) combined with in vivo epistasis rescue experiments\",\n      \"pmids\": [\"28167794\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Gata4 directly represses Gata6 transcription via repressive cis-regulatory sites within 1 kb upstream of the Gata6 TSS, identified by ChIP-qPCR and luciferase reporter assay. In Gata4 haploinsufficient SHF cells, enhanced Gata6 expression is observed, consistent with GATA4-mediated repression of Gata6.\",\n      \"method\": \"ChIP-qPCR, luciferase reporter assay, Gata4 haploinsufficient mouse model with SHF gene expression analysis\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and reporter assays support direct repression; single lab, consistent with in vivo data\",\n      \"pmids\": [\"31120883\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"GATA4 is a pioneer factor for estrogen receptor alpha (ERα) in osteoblasts: maximal GATA4 binding to chromatin precedes ERα binding, GATA4 is required for H3K4 dimethylation at ERα binding sites, and GATA4 knockdown reduces ERα recruitment to DNA. GATA4 and ERα co-occupy chromatin near osteoblast-specific genes controlling differentiation.\",\n      \"method\": \"ChIP-seq (GATA4 and ERα), ChIP for H3K4me2, GATA4 knockdown with ERα recruitment analysis\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq plus functional KD; single lab, pioneer factor role defined by sequential binding and chromatin mark analysis\",\n      \"pmids\": [\"21566084\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GATA4 directly binds to two Runx2 promoters and an enhancer region (by ChIP). GATA4 binding maintains open chromatin (H3K4me2, H3K27ac marks) at the Runx2 locus; GATA4 knockdown reduces open chromatin marks and increases H3K27me2 (closed chromatin mark) at Runx2, reducing Runx2 expression and osteoblast mineralization in vitro and in vivo.\",\n      \"method\": \"ChIP (GATA4, H3K4me2, H3K27ac, H3K27me2), DNase I hypersensitivity assay, Gata4 conditional KO (Col1a1-Cre), osteoblast differentiation assays\",\n      \"journal\": \"JBMR plus\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-based chromatin analysis plus in vivo KO; single lab, pioneer factor role supported by chromatin accessibility data\",\n      \"pmids\": [\"30035248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"GATA-4 binds to the erythropoietin (EPO) gene promoter with the most prominent binding activity among GATA factors expressed in hepatocytes (by EMSA and in vivo ChIP). RNAi-mediated inhibition of GATA-4 expression dramatically reduces Epo gene transcription in Hep3B hepatoma cells.\",\n      \"method\": \"EMSA, chromatin immunoprecipitation (in vivo), siRNA knockdown with RT-PCR quantification of Epo transcription\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo DNA binding plus siRNA functional validation; single lab\",\n      \"pmids\": [\"14583613\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"GATA4 regulates Sertoli cell function including blood-testis barrier (BTB) integrity and lactate metabolism. GATA4 depletion in Sertoli cells alters expression of tight/adherens junction genes (Tjp1, Cldn12, Vcl, Tnc, Csk) and extracellular matrix genes, reduces tight junction protein-1 levels, disrupts junctional complexes, decreases epithelial membrane resistance, and impairs lactate production.\",\n      \"method\": \"Conditional Sertoli cell Gata4 KO (Amhr2-Cre), siRNA knockdown in TM4 cells, microarray, qRT-PCR, western blotting, immunocytochemistry, metabolomic profiling\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo conditional KO plus in vitro gene silencing plus metabolomics; single lab\",\n      \"pmids\": [\"26974005\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Parkin (E3 ubiquitin ligase) directly interacts with GATA4 (by co-immunoprecipitation) and promotes its ubiquitination. Parkin overexpression decreases GATA4 protein (but not mRNA) in the kidney; Parkin-mediated GATA4 degradation limits downstream GATA4/GAS1 signaling and reduces premature senescence, inflammation, and fibrosis in diabetic nephropathy.\",\n      \"method\": \"Co-immunoprecipitation, Parkin overexpression and knockout in mice, GATA4 ubiquitination assay, high-glucose cell culture model\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ubiquitination assay plus in vivo KO/OE; single lab\",\n      \"pmids\": [\"32436607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"GATA4 inhibits doxorubicin-induced autophagy in cardiomyocytes as a mechanism of cardioprotection. GATA4 overexpression upregulates Bcl2 expression and suppresses DOX-induced activation of autophagy-related genes. GATA4 depletion triggers autophagy that renders cardiomyocytes more sensitive to DOX toxicity.\",\n      \"method\": \"LC3-II autophagic flux assays, bafilomycin A1 treatment, GATA4 siRNA and adenoviral overexpression, cell death assays, Bcl2 mRNA/protein analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple autophagy flux assays plus genetic gain/loss-of-function with mechanistic target (Bcl2); single lab\",\n      \"pmids\": [\"19901028\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Notch downstream effectors HEY1, HEY2, and HEYL differentially regulate GATA4-dependent promoters (STAR protein, P450 aromatase, 3β-HSD), and HEY/HES binding sites are present in these promoters. Notch signaling thus represses GATA4-induced steroidogenic gene expression.\",\n      \"method\": \"Constitutively active Notch constructs, Notch inhibitor treatment of follicles and Leydig cells, luciferase reporter assays with GATA4-dependent promoters, HEY/HES binding site analysis\",\n      \"journal\": \"Reproduction\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — reporter assays in cell lines; direct physical interaction not shown; single lab, limited mechanistic depth\",\n      \"pmids\": [\"26183893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Nuclear PKM2 (S37P-PKM2) in cardiomyocytes interacts with GATA4, GATA6, and P53. Nuclear PKM2 prevents caspase-1-dependent cleavage and degradation of GATA4/6. TRIM35 (E3 ubiquitin ligase) promotes ubiquitination-dependent loss of nuclear PKM2, which in turn destabilizes GATA4/6 and permits P53 accumulation, leading to cardiac dysfunction.\",\n      \"method\": \"Co-immunoprecipitation (nuclear PKM2 with GATA4/6), cardiomyocyte-specific PKM2 and TRIM35 transgenic/KO mice, caspase-1 cleavage assays, cardiac function measurements\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus in vivo genetic models plus caspase cleavage mechanistic link; single lab\",\n      \"pmids\": [\"36322626\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GATA4 directly binds the VEGFA and VEGFC promoters and enhances their transcription in fibroblast-like synoviocytes (FLS). GATA4 loss-of-function attenuates VEGF secretion from RA FLS, reduces endothelial cell proliferation, migration, and tube formation, and suppresses collagen-induced arthritis development and RA-augmented angiogenesis in vivo.\",\n      \"method\": \"ChIP (GATA4 at VEGFA/VEGFC promoters), GATA4 siRNA knockdown, endothelial tube formation and migration assays, CIA mouse model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-based direct target identification plus in vitro and in vivo loss-of-function; single lab\",\n      \"pmids\": [\"29717129\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"GATA4 (together with Sp1) directly regulates transcription of the erythropoietin receptor (EpoR) in cardiomyocytes. GATA4 and Sp1 bind the EpoR 5' flanking region (by EMSA and ChIP). Forced GATA4 expression induces EpoR mRNA; GATA4 knockdown (in vitro and in an inducible shRNA transgenic mouse) reduces EpoR transcription. The Sp1 site is essential for GATA4-mediated EpoR transcription.\",\n      \"method\": \"EMSA, ChIP, luciferase reporter assays, siRNA knockdown, adenoviral GATA4 overexpression, inducible shRNA transgenic mice\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA plus ChIP plus in vivo transgenic validation; single lab\",\n      \"pmids\": [\"21029371\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Gata4 directly represses EPAS1 (HIF2α) in hepatic stellate cells (by ChIP). GATA4 overexpression in hepatic stellate cells induces fibrosis regression; GATA4 absence causes hepatic stellate cell activation and fibrosis.\",\n      \"method\": \"ChIP, adenoviral Gata4 overexpression, conditional Gata4 KO in mice, CCl4 fibrosis model\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-based direct target identification with in vivo gain/loss-of-function; single lab\",\n      \"pmids\": [\"34699385\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Intestinal epithelial GATA4 controls bacterial colonization and inflammatory immunity in the proximal small intestine by regulating retinol metabolism and luminal IgA. Loss of jejunal GATA4 permits pathogenic inflammatory responses (including segmented filamentous bacteria-driven IL-17 immunity) that disrupt barrier function and increase mortality upon infection.\",\n      \"method\": \"Intestinal epithelium-specific Gata4 conditional KO, germ-free mouse colonization experiments, gene expression analysis, IgA measurement, retinol metabolism analysis, in vivo infection model\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo conditional KO with mechanistic pathway (retinol metabolism, IgA) identification; single study\",\n      \"pmids\": [\"36630917\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"GATA4 regulates Sertoli cell function in adult mice; conditional deletion of Gata4 in Sertoli cells (Amhr2-Cre) causes age-dependent testicular atrophy, impaired spermatogenesis, decreased sperm quantity and motility, increased blood-testis barrier permeability, and loss of fertility.\",\n      \"method\": \"Conditional Sertoli cell Gata4 knockout (Amhr2-Cre/loxP), histology, RT-PCR, sperm analysis, fertility testing\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo conditional KO with multiple defined cellular phenotypes; single lab\",\n      \"pmids\": [\"21172404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"GATA4 physically interacts with Sp1 (demonstrated by GST pull-down assay) and synergistically activates the ANF promoter. ERK1/2-mediated phosphorylation of GATA4 enhances the affinity between GATA4 and Sp1. Both GATA4 and Sp1 are recruited to the ANF promoter during phenylephrine-induced hypertrophy (by ChIP). Sp3 antagonizes this interaction and represses transcriptional synergy.\",\n      \"method\": \"GST pull-down, ChIP, luciferase reporter assays, hypertrophic cardiomyocyte model (phenylephrine), ERK inhibitor treatment\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — GST pull-down plus ChIP plus reporter assays; single lab\",\n      \"pmids\": [\"20874724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GATA4 and GATA6 repress transcription through the sonic hedgehog endoderm-specific enhancer MACS1 in the pancreatic endoderm; GATA-binding sites within MACS1 are necessary for this repressive activity. Loss of both Gata4 and Gata6 in the pancreas leads to ectopic hedgehog pathway activation and conversion of pancreatic fates into intestinal or stomach lineages.\",\n      \"method\": \"Conditional Gata4/Gata6 double KO (Pdx1-Cre), luciferase reporter assays (MACS1 enhancer with GATA-site mutations), in situ hybridization, immunostaining for lineage markers\",\n      \"journal\": \"Development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct repressor activity via reporter assays with GATA-site mutations plus in vivo genetic validation; single lab\",\n      \"pmids\": [\"26932670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Rubicon, a negative regulator of autophagy, prevents autophagic degradation of GATA4 in Sertoli cells. Rubicon-null Sertoli cells show elevated autophagy flux and reduced GATA4 protein levels, causing spermatogenesis defects. Androgens regulate Rubicon levels in testis, thereby indirectly controlling GATA4 protein stability through autophagic degradation.\",\n      \"method\": \"Rubicon systemic and Sertoli cell-specific KO mice, autophagy flux assays, GATA4 protein quantification, androgen antagonist treatment\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo Sertoli-specific KO plus autophagy flux analysis plus pharmacologic manipulation; single lab\",\n      \"pmids\": [\"34351902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Kindlin-2 suppresses GATA4 expression by binding to the GATA4 promoter and recruiting histone methyltransferase SUV39H1, which deposits repressive H3K9 di- and tri-methylation marks. Cardiac-specific Kindlin-2 deletion in mice causes hypertrophic cardiomyopathy with markedly elevated GATA4 expression.\",\n      \"method\": \"ChIP (Kindlin-2, SUV39H1, H3K9me2/3 at GATA4 promoter), co-immunoprecipitation (Kindlin-2/SUV39H1), cardiac-specific Kindlin-2 KO mice, isoproterenol treatment\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus Co-IP plus in vivo KO; single lab\",\n      \"pmids\": [\"31767831\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GATA4 and GATA6 occupy chromatin near the Dll1 (Notch ligand) transcription start site (by ChIP), suggesting direct regulation of Dll1. Double knockout of GATA4 and GATA6 in intestinal epithelium reduces Notch signaling (decreased Dll1 and Olfm4 expression), increases goblet cell differentiation, and increases proliferation.\",\n      \"method\": \"Double conditional KO (Villin-Cre), ChIP for GATA4 at Dll1 TSS, cell-type marker analysis, Notch pathway gene expression\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus in vivo double KO with Notch pathway phenotype; single lab\",\n      \"pmids\": [\"24929016\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GATA4 binds chromatin near Cyclin D2 (Ccnd2), Cdk6, and Frizzled 5 (Fzd5) genes in developing intestinal epithelium (by ChIP), and their transcripts are reduced in GATA4-deficient intestinal epithelium, placing them as direct GATA4 targets controlling early intestinal epithelial proliferation.\",\n      \"method\": \"ChIP (GATA4 at Ccnd2, Cdk6, Fzd5), SHH-Cre Gata4 conditional KO embryos, proliferation assays, qRT-PCR\",\n      \"journal\": \"Cellular and molecular gastroenterology and hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-based direct target identification plus in vivo KO phenotype; single lab\",\n      \"pmids\": [\"27066525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The Gata4 G295S mutation functions as a hypomorph in vivo: it can activate downstream targets in endoderm but not in the developing heart. It causes cardiomyocyte proliferation deficits and decreased cardiac expression of CCND2 (a direct Gata4 target and cyclin family member). In vitro, the mutant protein has reduced DNA-binding affinity and transcriptional activity and abolishes physical interaction with TBX5.\",\n      \"method\": \"Gata4 G295S knock-in mice, compound mutants with Gata4 null allele, cardiomyocyte proliferation analysis, gene expression (Ccnd2), in vitro transcriptional and DNA-binding assays\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo knock-in mouse model with defined proliferation phenotype plus in vitro mechanistic dissection; single lab\",\n      \"pmids\": [\"22589735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A GATA4-dependent secretory program (including chemokine CCL2) promotes non-cell-autonomous tumor suppression by recruiting cytotoxic CD8 T cells. GATA4-dependent tumor suppression in mice requires cytotoxic CD8 T cells and is partially dependent on CCL2.\",\n      \"method\": \"Gata4 loss-of-function and overexpression mouse tumor models, CD8 T cell depletion, CCL2 neutralization, tumor growth assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo mouse tumor models with immune cell depletion epistasis; single lab\",\n      \"pmids\": [\"35017504\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GATA4 directly binds the GNAI3 promoter in dental papilla mesenchymal cells (confirmed by dual-luciferase and ChIP assays both in vitro and in vivo). GATA4 deletion reduces GNAI3 expression, and GNAI3 knockdown impairs odonto/osteogenic differentiation of stem cells of dental apical papilla.\",\n      \"method\": \"Wnt1-Cre Gata4 conditional KO mice, ChIP, dual-luciferase assay, GNAI3 siRNA knockdown, stem cell differentiation assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter assay plus in vivo KO; single lab\",\n      \"pmids\": [\"28484278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"GATA-4 binds to a GATA site in the hepcidin (HAMP) promoter (by EMSA and gel retardation), and mutation of this site impairs hepcidin promoter activity. GATA-4 co-transfection enhances hepcidin promoter activity, and siRNA-mediated GATA4 knockdown reduces endogenous hepcidin expression in HepG2 cells. The GATA-binding site is also required for IL-6-induced hepcidin expression but not BMP-6 response.\",\n      \"method\": \"EMSA, luciferase reporter assays with GATA-site mutations, GATA4 siRNA knockdown, co-transfection in hepatoma cells\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — EMSA plus reporter and siRNA in hepatoma cell line; no ChIP or in vivo validation; single lab\",\n      \"pmids\": [\"21609320\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Meox1 activates Gata4 transcription directly; Meox1 occupies the Gata4 promoter (demonstrated by ChIP) and activates Gata4 promoter activity (luciferase assay). Meox1-driven pathological hypertrophy is mediated through downstream Gata4 activation; Gata4 knockdown abolishes Meox1-induced hypertrophy.\",\n      \"method\": \"ChIP (Meox1 at Gata4 promoter), luciferase reporter assay, Gata4 siRNA rescue, Meox1 overexpression and knockdown mouse models (TAC, FHCM)\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter plus in vivo mouse models; single lab\",\n      \"pmids\": [\"29155983\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SIRT7 (class III histone deacetylase) promotes deacetylation of GATA4, inhibiting its transcriptional activity. GATA4 normally induces ovarian cancer cell senescence by inhibiting Wnt signaling; SIRT7-mediated deacetylation of GATA4 suppresses this senescence-inducing activity and promotes tumor progression.\",\n      \"method\": \"Co-immunoprecipitation (SIRT7-GATA4), gain/loss-of-function experiments in OC cell lines, luciferase reporter assays, nude mouse xenograft model\",\n      \"journal\": \"Gynecologic oncology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — Co-IP plus reporter assays plus xenograft; deacetylation mechanism inferred without direct acetylation site mapping; single lab\",\n      \"pmids\": [\"36804620\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GATA4 is a zinc-finger pioneer transcription factor whose activity is governed by multiple post-translational modifications (sumoylation by PIAS1 at K366, acetylation by p300 promoting homomultimerization, deacetylation by HDAC2/Hopx or SIRT7, phosphorylation by MAPK/PKC, caspase-1-mediated cleavage, and proteasomal degradation via CHIP or Parkin), and which exerts its transcriptional effects through lineage-specific interactions with co-factors including TBX5, NKX2-5, ETS1, SRF, BAF60c, Cyclin D2, ERRγ/PGC-1α, STAT1, and the CHD4/NuRD repressor complex; in cardiomyocytes and endocardial cells it acts as a pioneer factor whose genome occupancy is directed by partner TFs (NKX2-5 or ETS1), it controls cardiomyocyte proliferation through direct transcription of CCND2 and CDK4, and it regulates senescence/SASP by being a selective autophagy substrate whose stabilization (dependent on ATM/ATR) activates NF-κB.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GATA4 is a zinc-finger pioneer transcription factor that establishes and maintains lineage-specific gene expression programs across cardiac, endothelial, endodermal, skeletal, and gonadal tissues by opening chromatin and directing partner transcription factors to their targets [#13, #20]. Its pioneering activity is lineage-resolved: co-expressed non-pioneer factors NKX2-5 (cardiomyocytes) and ETS1 (endocardial cells) physically bind GATA4 and redirect its genome-wide occupancy, augmenting chromatin opening, and GATA4 likewise acts upstream of estrogen-receptor-alpha and Runx2 by depositing activating chromatin marks before partner recruitment in osteoblasts [#13, #20, #21]. In the developing heart GATA4 forms higher-order complexes with TBX5, NKX2-5, SRF, Cyclin D2, ERR\\u03b3, and BAF60c to activate contractile and cell-cycle genes, and it cooperates with TBX5 to directly transactivate the cyclins CCND2/CDK4 driving cardiomyocyte proliferation; the human disease G296S/G295S mutation disrupts the GATA4\\u2013TBX5 interaction at cardiac super-enhancers, causing septation defects and proliferation deficits [#3, #4, #6, #8, #12, #39]. GATA4 also functions as a direct transcriptional repressor through the CHD4/NuRD complex and through repressive cis-elements, silencing skeletal/smooth muscle genes in the heart, repressing GATA6, hedgehog enhancers, and EPAS1/HIF2\\u03b1 in stellate cells [#11, #19, #34, #17]. Beyond the heart GATA4 specifies liver sinusoidal endothelial cell identity and protects against perisinusoidal fibrosis by repressing MYC-driven profibrotic angiocrine signaling, and controls intestinal epithelial immunity, Sertoli cell barrier function, and steroidogenesis [#15, #16, #31, #32]. GATA4 protein abundance is governed by an extensive set of post-translational controls: sumoylation by PIAS1 at K366 enhances activity and nuclear occupancy, p300 acetylation drives homomultimerization and DNA binding while HDAC2/Hopx and SIRT7 reverse it, MAPK/PKC/ERK phosphorylation enhances DNA binding and cofactor affinity, and the protein is destroyed by CHIP- and Parkin-mediated proteasomal degradation, caspase-1 cleavage, and p62/Rubicon-regulated selective autophagy [#1, #2, #14, #33, #9, #24, #10, #35]. In senescence, suppression of autophagic GATA4 turnover stabilizes the protein in an ATM/ATR-dependent manner, activating NF-\\u03baB to drive the senescence-associated secretory phenotype [#0].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Established that GATA4 does not act alone but assembles into higher-order transcription factor complexes on cardiac promoters, defining the combinatorial logic of cardiac gene activation.\",\n      \"evidence\": \"Cotransfection reporter assays and DNA-binding mutant analysis on the cardiac alpha-actin promoter with Nkx2-5 and SRF\",\n      \"pmids\": [\"11983708\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physical interaction inferred from functional cooperativity rather than direct Co-IP\", \"Heterologous cell systems only\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identified sumoylation as a positive post-translational control of GATA4, showing that a specific modification site and E3 ligase tune both activity and nuclear localization.\",\n      \"evidence\": \"In vitro sumoylation assay, K366R mutagenesis, and reporter assays identifying PIAS1 as the SUMO E3 ligase\",\n      \"pmids\": [\"15337742\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological contexts where sumoylation is regulated not defined\", \"Interplay with other PTMs at adjacent residues unaddressed\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showed that reversible acetylation gates GATA4's cell-cycle gene program, linking a chromatin-modifying complex to restraint of cardiomyocyte proliferation during development.\",\n      \"evidence\": \"Co-IP, Hopx/Hdac2 knockout mice, and transactivation assays with interaction domain mapping\",\n      \"pmids\": [\"20833366\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific acetylated lysines not mapped here\", \"Counteracting acetyltransferase not identified in this study\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Generalized GATA4's pioneer role beyond the heart, demonstrating it opens chromatin and licenses recruitment of nuclear receptors and osteogenic factors in bone.\",\n      \"evidence\": \"ChIP-seq for GATA4, ER\\u03b1, and H3K4me2, plus GATA4 knockdown in osteoblasts; ChIP and DNase hypersensitivity at Runx2\",\n      \"pmids\": [\"21566084\", \"30035248\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab data for each tissue\", \"Mechanism of GATA4 nucleosome engagement not structurally resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined direct GATA4 transcriptional targets and cofactors driving cardiomyocyte proliferation, connecting GATA4/TBX5 cooperativity to cyclin/CDK gene control.\",\n      \"evidence\": \"Co-IP, ChIP, transactivation assays, lineage-specific knockouts, and Xenopus cardiogenesis for CCND2/CDK4 and Cyclin D2 coactivation\",\n      \"pmids\": [\"24858909\", \"24474767\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cyclin D2 acts CDK-independently but the structural basis is unresolved\", \"Relative contributions of GATA4 vs TBX5 at each target not fully separated\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Distinguished context-dependent functional domains and phosphosites of GATA4, showing that cardiac versus endoderm activities and survival versus cardiogenesis depend on separable residues.\",\n      \"evidence\": \"Domain deletion and S105 point mutagenesis, BAF60c synergy assays, and Gata4 G295S knock-in mice with proliferation and Ccnd2 analysis\",\n      \"pmids\": [\"22473995\", \"22589735\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Upstream kinase regulating S105 in vivo not pinned down\", \"Tissue-selective hypomorphism mechanism partially explained\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Mechanistically explained a human congenital heart disease mutation by showing it abolishes GATA4\\u2013TBX5 cobinding at super-enhancers and corrupts both activation and repression programs.\",\n      \"evidence\": \"Patient iPSC-cardiomyocytes with ChIP-seq, ATAC-seq, and functional contractility/calcium assays for GATA4-G296S\",\n      \"pmids\": [\"27984724\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Allele-specific contributions to each dysregulated gene set not isolated\", \"Therapeutic reversibility untested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established GATA4 as a direct transcriptional repressor in endoderm lineages, restraining hedgehog and alternative fate programs together with GATA6.\",\n      \"evidence\": \"Conditional Gata4/Gata6 double knockouts with reporter assays mutating GATA sites at the Shh MACS1 enhancer and Dll1 ChIP\",\n      \"pmids\": [\"26932670\", \"24929016\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Corepressor machinery at these elements not defined in these studies\", \"GATA4 versus GATA6 individual contributions overlap\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Revealed that GATA4 protein stability is a senescence switch, with loss of selective autophagic degradation stabilizing GATA4 to drive inflammatory SASP independent of canonical p53/p16.\",\n      \"evidence\": \"Genetic LOF, autophagy flux assays, p62 knockdown, ATM/ATR inhibition epistasis, and NF-\\u03baB reporters\",\n      \"pmids\": [\"26404840\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How DNA damage signaling mechanistically blocks p62 recognition of GATA4 not resolved\", \"Direct GATA4 NF-\\u03baB target genes not enumerated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Expanded the GATA4 degradation network to multiple E3 ligases and proteases, showing CHIP, Parkin, caspase-1, and Rubicon-regulated autophagy converge on GATA4 abundance in disease contexts.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, in vivo KO/OE for Parkin and CHIP, caspase-1 cleavage with HSP70 protection, and Rubicon Sertoli-specific KO\",\n      \"pmids\": [\"32436607\", \"17525155\", \"25501827\", \"34351902\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubiquitin chain types and degron mapping incomplete\", \"Cross-talk between these competing turnover routes not integrated\", \"Mostly single-lab studies per ligase\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Resolved how a single pioneer factor achieves lineage-specific genome occupancy, showing partner TFs NKX2-5 and ETS1 redirect GATA4 binding and chromatin opening in cardiomyocytes versus endocardium.\",\n      \"evidence\": \"Lineage-specific biotinylated GATA4 ChIP-seq, ATAC-seq, Co-IP, scRNA-seq, and endothelial Gata4 KO with reporter validation\",\n      \"pmids\": [\"36263775\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Biophysical basis of ETS1's greater pioneering potency unexplained\", \"Generality to non-cardiac partners untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Connected GATA4 to chromatin-modifying repressor and coactivator complexes and to metabolic/contractile gene partitioning, defining its activating and repressive arms in the heart.\",\n      \"evidence\": \"Mass spectrometry, Co-IP, ChIP-seq, RNA-seq, and CRISPR silencer deletion for CHD4/NuRD; Co-IP and ChIP-seq for ERR\\u03b3/PGC-1\\u03b1 cooperativity\",\n      \"pmids\": [\"35450884\", \"35418170\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Switch between GATA4-CHD4 repression and GATA4 coactivation not mechanistically defined\", \"How disease mutations selectively impair cooperativity unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Linked GATA4 homomultimerization to acetylation-driven activation, providing a structural basis for how p300 acetylation activates GATA4 DNA binding in hypertrophy.\",\n      \"evidence\": \"Multimerization assays, domain mutagenesis (residues 308-326), acetylation and DNA-binding assays, and cardiomyocyte hypertrophy assays\",\n      \"pmids\": [\"35173540\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Multimer stoichiometry and structure not determined\", \"Single-lab biochemistry\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Extended GATA4 function to organ identity and physiology in the liver and intestine, showing it specifies endothelial fate, suppresses fibrosis, and gates mucosal immunity.\",\n      \"evidence\": \"Lineage-specific conditional knockouts with ChIP-seq/ATAC-seq (LSEC, MYC/Pdgfb, EPAS1) and germ-free colonization/infection models with retinol and IgA analysis\",\n      \"pmids\": [\"28218627\", \"32916216\", \"34699385\", \"36630917\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether GATA4 pioneering directly underlies these tissue programs not always tested\", \"Upstream signals controlling GATA4 in these tissues unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the competing post-translational modifications and degradation pathways are integrated in real time to set GATA4 levels and target selectivity within a given cell remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unified model coordinating SUMO/acetylation/phosphorylation with autophagic vs proteasomal vs proteolytic turnover\", \"Structural basis of pioneer nucleosome engagement undefined\", \"Direct genome-wide GATA4 target sets in non-cardiac tissues incompletely mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [3, 4, 8, 11, 13, 19, 34]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [5, 14, 22, 29, 39, 42]},\n      {\"term_id\": \"GO:0003700\", \"supporting_discovery_ids\": [13, 20, 21]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 27]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [3, 13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 4, 13]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [8, 15, 18, 34]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [11, 16, 20, 21]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"complexes\": [\"CHD4/NuRD repressor complex\"],\n    \"partners\": [\"TBX5\", \"NKX2-5\", \"ETS1\", \"SRF\", \"CHD4\", \"CCND2\", \"ESRRG\", \"STAT1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}